

# Index

- <sup>13</sup>C-octanoic breath test, 1341, 1481  
<sup>13</sup>C-urea breath test, 553  
 4-aminosalicylic acid, 1771  
 5-aminosalicylic acid, 647, 207  
 5-HT<sub>3</sub> mechanisms, 225  
 5-HT<sub>3</sub> receptor antagonist, 119  
 5-HT<sub>3</sub> receptors, 1563  
 5-hydroxytryptamine, 623  
 6-mercaptopurine, 647  
 6-thioguanine nucleotides,  
 12-month course, 243
- α-antagonist, 1801  
 α-4 integrin, 699  
 α-tocopherol, 985  
 abdominal irradiation, 623  
 Abe, H. *see* Murakami, K.  
 Abitbol, V., Mary, J.Y., Roux, C., Soulé, J.C., Belaiche, J.,  
 Dupas, J.-L., Gendre, J.P., Lerebours, E., Chaussade, S. & the  
 Groupe d' Etudes Thérapeutiques des Affections  
 Inflammatoires Digestives (GETAID). Osteoporosis in  
 inflammatory bowel disease: effect of calcium and vitamin D  
 with or without fluoride, 919  
 absorption, 769  
 ABT-229, 749, 1481  
 acetaminophen, 707, 1539  
 acid, 303, 1469  
 acid inhibition, 425  
 acid secretion, 1723  
 acidity, 455  
 acute pancreatitis, 2097  
 Adachi, K., Ono, M., Kawamura, A., Yuki, M., Fujishiro, H. &  
 Kinoshita, Y. Nizatidine and cisapride enhance salivary  
 secretion in humans, 297  
 Adachi, K. *see* Hashimoto, T.  
 Adamo, S. *see* Rizzello, F.  
 Adams, G. *see* Malik, A.H.  
 adenosine triphosphate, 325  
 adjuvant chemotherapy, 353  
 adrenergic receptors, 1801  
 adverse effects, 27  
 Africa, 595  
 agents, 603  
 aging, 683  
 Ahmed, F. *see* Tutuian, R.  
 Ahn, D.S. *see* Choi, I.J.  
 Aichbichler, B. *see* Högenauer, C.  
 AIDS, 595, 799  
 Aisowmely, A.M. & Hodgson, H.J.F. Review article: non-surgical  
 treatment of hepatocellular carcinoma, 1  
 Akamatsu, T. *see* Futagami, S.  
 Akkermans, L.M.A. *see* De Schryver, A.M.P.  
 Alampi, G. *see* Bazzoli, F.  
 albendazole, 595  
 alcohol, 497, 985  
 alimentary diseases, 1709  
 Allan, A. *see* Hulin, S.J.  
 allergies, 969  
 Allez, M. *see* Sabate, J.M.  
 alosetron, 225, 985  
 alverine citrate, 1187  
 amantadine, 2107  
 aminosaliclates, 79, 197  
 Amlot, P.L. *see* Gordon, F.H.  
 amoxicillin, 137, 793, 1163, 2067  
 ampicillin, 1163  
 amylose-ethylcellulose coating, 1771  
 anal anastomosis, 27  
 anal fissures, 101  
 Anderloni, A. *see* Parente, F.  
 Andreoli, A. *see* Armuzzi, A.  
 Andreu, V. *see* Calvet, X.  
 Andriesse, G.I. *see* De Schryver, A.M.P.  
 Andriulli, A. *see* Perri, F.  
 Andus, T. *see* Musch, E.  
 Annese, V. *see* Rizzello, F.  
 Annibale, B., Di Giulio, E., Caruana, P., Lahner, E., Capurso, G.,  
 Bordi, C. & Delle Fave, G. The long-term effects of cure of  
*Helicobacter pylori* infection on patients with atrophic body  
 gastritis, 1723  
 Annibale, B. *see* Lahner, E.  
 Ansari, A., Hassan, C., Duley, J., Marinaki, A., Shobowale-Bakre,  
 E.-M., Seed, P., Meenan, J., Yim, A. & Sanderson, J. Thiopurine  
 methyltransferase activity and the use of azathioprine in  
 inflammatory bowel disease, 1743  
 antacids, 435, 2029  
 anterior cingulate cortex, 1357  
 Anthony, A. *see* Wakefield, A.J.  
 antibiotic prophylaxis, 727  
 antibiotic therapy, 1715  
 antibiotics, 291, 909, 1083, 1461  
 antibiotics resistance, 793  
 anticonvulsants, 1539  
 antidepressant, 1091  
 antidepressants, 1539  
 antigens, 533  
 antioxidants, 197, 1997  
 antisecretory agents, 1945  
 antisense, 1761  
 anti-TNF, 1101  
 Antoni, I. *see* Feydt-Schmidt, A.  
 antrum, 129

- anxiety, 2081  
 APC2059, 407  
 Appelman, S.A. *see* Huang, J.-Q.  
 appropriateness, 1443  
 Aranha, G. *see* Avidan, B.  
 Arguedas, M.R. *see* Thompson, B.F.  
 Arita, T. *see* Murakami, K.  
 Armuzzi, A., Candelli, M., Zocco, M.A., Andreoli, A., De Lorenzo, A., Nista, E.C., Miele, L., Cremonini, F., Cazzato, I.A., Grieco, A., Gasbarrini, G. & Gasbarrini, A. Review article: breath testing for human liver function assessment, 1977  
 Arnott, I.D.R., Watts, D. & Ghosh, S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? 857  
 Arnout, J. *see* Van Hecken, A.  
 Arroyo, M.T. *see* Serrano, P.  
 Artikis, V. *see* Georgopoulos, S.D.  
 Asano, T. *see* Saitoh, T.  
 Ascione, T. *see* Gaeta, G.B.  
 Asgharian, B. *see* Bashir, S.  
 aspirin, 497, 929, 1945  
 Athanasakis, E., Chrysos, E., Zoras, O.J., Tsiaoussis, J., Karkavitsas, N. & Xynos, E. Octreotide enhances the accelerating effect of erythromycin on gastric emptying in healthy subjects, 1563  
 Atherton, J.C. *see* Stack, W.A.  
 atrophic body gastritis, 507, 1723  
 atrophic gastritis, 515  
 atrophy, 1923  
 atropic gastritis, 1449  
 atropine, 17  
 autoimmune disease, 1241  
 autoimmune gastritis, 281  
 Avenhaus, W. *see* Ullerich, H.  
 Avidan, B., Sonnenberg, A., Bhatia, H., Aranha, G., Schnell, T.G. & Sontag, S.J. Inguinal hernia is not a sign of colon cancer: results of a prospective screening trial, 1197  
 Avidan, B., Sonnenberg, A., Schnell, T.G. & Sontag, S.J. There are no reliable symptoms for erosive oesophagitis and Barrett's oesophagus: endoscopic diagnosis is still essential, 735  
 Axon, A. *see* Mallertheiner, P.  
 Axon, A.T.R. *see* Mason, J.  
 Ayub, K. *see* Verghese, V.J.  
 azathioprine, 79, 181, 389, 647, 1125, 1225, 1743, 1751, 2061  
 baclofen, 17, 869, 1655  
 Bai, J.C. *see* Sambuelli, A.  
 Baisley, K. *see* Warrington, S.  
 Baj, M. *see* Sengupta, S.  
 Bajador, E. *see* Lanás, A.  
 Ball, D. *see* Shaw, I.S.  
 balsalazide, 6, 691  
 Balzano, A. *see* Manes, G.  
 Banna, N. *see* Langmead, L.  
 Barabino, A., Torrente, F., Castellano, E., Gandullia, P., Calvi, A., Cucchiara, S., de'Angelis, G.L., Fontana, M., Lionetti, P., De Giacomo, C. & Gissi, A. The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience, 1503  
 Barabino, A., Torrente, F., Ventura, A., Cucchiara, S., Castro, M. & Barbera, C. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey, 1125  
 Barbera, C. *see* Barabino, A.  
 Bargiggia, S. *see* Parente, F.  
 Barish, C. *see* Sands, B.E.  
 Barish, C. *see* Yacyshyn, B.R.  
 Baron, J.H. & Sonnenberg, A. Alimentary diseases in the poor and middle class in London 1773–1815, and in New York poor 1797–1818, 1709  
 Barrett's oesophagus, 735, 887, 893, 1795  
 Barth, J.A. *see* Gardner, J.D.  
 Bartolozzi, F. *see* Cremonini, F.  
 Bartolozzi, F. *see* Di Caro, S.  
 Bashir, S., Gibril, F., Ojeburu, J.V., Asgharian, B., Entsua, L.K., Ferraro, G., Crafa, P., Bordi, C. & Jensen, R.T. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas, 1367  
 Basit, A.W. *see* Tuleu, C.  
 Basilisco, G. *see* Massironi, S.  
 Bates, J. *see* Rubin, G.  
 Bayerdörfler, E. *see* Mallertheiner, P.  
 Bazzoli, F., Zagari, R.M., Pozzato, P., Fossi, S., Ricciardiello, L., Nicolini, G., De Luca, L., Berretti, D., Alampi, G., Di Pietro, C., Morelli, P. & Roda, E. Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of *Helicobacter pylori* infection, 153  
 Büchler, M.W. *see* Netzer, P.  
 beclometasone dipropionate, 1109  
 Belaiche, J. *see* Abitbol, V.  
 Bella, M.R. *see* Calvet, X.  
 Benito, R. *see* Lanás, A.  
 Benson, M.J. *see* Zar, S.  
 benzodiazepines, 361, 1539  
 Bergenheim, K. *see* Vakil, N.  
 Berman, S. *see* Mayer, E.A.  
 Bermejo, F. *see* Boixeda, D.  
 Bernal, I. *see* Domènech, E.  
 Bernard, B. *see* Goulenok, C.  
 Bernard, D. *see* Van Vlierberghe, H.  
 Bernasconi, G. *see* Ortiz, R.A.M.  
 Berretti, D. *see* Bazzoli, F.  
 beta-agonists, 1539  
 beta-antagonist, 1801  
 Bhat, K., Harper, A. & Gorard, D.A. Perceived food and drug allergies in functional and organic gastrointestinal disorders, 969  
 Bhatia, H. *see* Avidan, B.  
 Biagini, R. *see* Bilardi, C.  
 Biagini, R. *see* Zentilin, P.  
 Bianchi Porro, G. *see* Parente, F.  
 Bianchi Porro, G. *see* Stockbrügger, R.W.  
 bicarbonate, 297  
 Biemond, I. *see* Kamerling, I.M.C.  
 bifidobacteria, 587, 1669

- Bilardi, C. *see* Zentilin, P.
- Bilardi, C., Biagini, R., Dulbecco, P., Iritano, E., Gambaro, C., Mele, M.R., Borro, P., Tessieri, L., Zentilin, P., Mansi, C., Vigneri, S. & Savarino, V. Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of *Helicobacter pylori* infection. 1733
- Bilardi, C. *see* Zentilin, P.
- biliary disease. 1037
- biliary disorders. 1083
- bioartificial liver. 1547
- biologic response modifier. 399
- biological agents. 1579
- bisacodyl. 1327
- bismuth. 1457
- Bjorkman, D. *see* El-Serag, H.B.
- bleeding. 1137
- Bliesath, H. *see* Novick, J.
- bloating. 225, 1867
- Blum, A.L. *see* Holtmann, G.
- Blumer, J.L. *see* Orenstein, S.R.
- Bochenek, W. *see* Kovacs, T.O.G.
- Bochenek, W. *see* Tutuian, R.
- Bode, G. *see* Rothenbacher, D.
- Boeckxstaens, G.E.E. *see* Hirsch, D.P.
- Boeckxstaens, G.E.E. *see* Kuiken, S.D.
- Boerr, I. *see* Sambuelli, A.
- Boesiger, P. *see* Faas, H.
- Bogers, J.J.P.M. *see* De Block, C.E.M.
- Boix, J. *see* Domènech, E.
- Boixeda, D., Bermejo, F., Martín-De-Argila, C., López-Sanromán, A., Defarges, V., Hernández-Ranz, F., Milicua, J.M. & García-Plaza, A. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for *Helicobacter pylori* infection. 1457
- Bollani, S. *see* Stockbrügger, R.W.
- Bommelaer, G. *see* Hallerback, B.
- Bommelaer, G. *see* Marteau, P.
- Bonanno, G. *see* Caletti, G.
- Bondesen, S. *see* Schiodt, F.V.
- bone. 919
- bone mineral density. 1519, 1895
- Bonnet, J. *see* Sabate, J.M.
- Bordi, C. *see* Annibale, B.
- Bordi, C. *see* Bashir, S.
- Bordi, C. *see* Lahner, E.
- Borquez, M.J. *see* Moreno-Montegudo, J.A.
- Borrelli, O. *see* Franzese, A.
- Borro, P. *see* Bilardi, C.
- Bortolotti, M., Coccia, G., Grossi, G. & Miglioli, M. The treatment of functional dyspepsia with red pepper. 1075
- Bory, F. *see* Calvet, X.
- Botta, F. *see* Giannini, E.
- Bouley, C. *see* Marteau, P.
- Bouvier, A.-M. *see* Faivre-Finn, C.
- Bouvier, M. *see* Marteau, P.
- bowel disorders. 1867
- bowel habit. 759
- Boyce, M. *see* Warrington, S.
- Bozzola, L. *see* Fabris, P.
- Braden, B., Enghofer, M., Schaub, M., Usadel, K.-H., Caspary, W.F. & Lembcke, B. Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. 1341
- breath tests. 1571
- Bredberg, E. *see* Hallerback, B.
- Brenner, H. *see* Rothenbacher, D.
- Brinkhoff, H. *see* Chen, C.L.
- Brinkmann, B.H. *see* Kuo, B.
- Brouwers, J.R.B.J. *see* Klok, R.M.
- Brown, J. *see* Mason, J.
- Börsch, G. *see* Peitz, U.
- Brullet, E. *see* Calvet, X.
- Bruno, R. *see* Gaeta, G.B.
- Brzezinski, A. *see* Tremaine, W.J.
- budesonide. 27
- Bujanda, L. *see* Elizalde, J.I.
- Burggraaf, J. *see* Kamerling, I.M.C.
- Burke, T.A. *see* Goldstein, J.L.
- Burman, C.-F. *see* Malfertheiner, P.
- Burton, D. *see* Kuo, B.
- Burton, D.D. *see* Cremonini, F.
- Buscarini, E. *see* Caletti, G.
- Buti, M. *see* San Miguel, R.
- butyl scopolamine bromide. 111
- butyrate. 325
- Bytzer, P. *see* Holtmann, G.
- Bytzer, P. *see* Madsen, L.G.
- C282Y. 1963
- Cabanne, A. *see* Sambuelli, A.
- Cabasés, J.M. *see* San Miguel, R.
- Cabrè, E. *see* Domènech, E.
- Caco-2. 1021
- cadherin. 1059
- Cadranel, J.F. *see* Goulenok, C.
- caesomorphine. 663
- cagA. 1015
- Cahill, J. *see* Van Den Bogaerde, J.
- Calafatti, S.A. *see* Ortiz, R.A.M.
- calcium. 919
- Caletti, G., Zinzani, P.L., Fusaroli, P., Buscarini, E., Parente, F., Federici, T., Peyre, S., De Angelis, C., Bonanno, G., Togliani, T., Pileri, S., Tura, S. & The Italian Gastric Lymphoma Study Group. The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma. 1715
- Calvet, X., Ducons, J., Guardiola, J., Tito, L., Andreu, V., Bory, F., Guirao, R. & The Group for Eradication Studies from Catalonia, Aragón (GRESCA). One-week triple vs. quadruple therapy for *Helicobacter pylori* infection — a randomized trial. 1261
- Calvet, X., Sanfeliu, I., Musulen, E., Mas, P., Dalmau, B., Gil, M., Bella, M.R., Campo, R., Brullet, E., Valero, C. & Puig, J. Evaluation of *Helicobacter pylori* diagnostic methods in patients with liver cirrhosis. 1283
- Calvet, X. *see* Vallve, M.

- Calvi, A. *see* Barabino, A.  
 Calza, L. *see* Manfredi, R.  
 Camartino, G. *see* Sambuelli, A.  
 Camilleri, M., Heading, R.C. & Thompson, W.G. Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome, 1407  
 Camilleri, M. *see* Cremonini, F.  
 Camilleri, M. *see* Kuo, B.  
 C-aminopyrine breath test, 717  
 Cammarota, G. *see* Di Caro, S.  
 Campanone, A. *see* Gaeta, G.B.  
 Campbell, M. *see* Hallerbäck, B.  
 Campbell, S., Kingstone, K. & Ghosh, S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine, 389  
 Campieri, M. *see* Mimura, T.  
 Campieri, M. *see* Rizzello, F.  
 Campo, R. *see* Calvet, X.  
 campylobacter, 1037  
 cancer registries, 353  
 cancer screening, 41  
 Candelli, M. *see* Armuzzi, A.  
 Candelli, M. *see* Di Caro, S.  
 Cange, L., Johnsson, E., Rydholm, H., Lehmann, A., Finizia, C., Lundell, L. & Ruth, M. Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease, 869  
 Cann, P.A. *see* Mansfield, J.C.  
 Capelli, G. *see* Cremonini, F.  
 Caprilli, R., Viscido, A. & Guagnozzi, D. Review article: biological agents in the treatment of Crohn's disease, 1579  
 capsaicin, 1075  
 Capurso, G. *see* Annibale, B.  
 Caratto, E. *see* Zentilin, P.  
 carbon-labelled breath tests, 1977  
 carcinoma, 1  
 cardiovascular, 577  
 cardiovascular disease, 1945  
 cardiovascular prophylaxis, 497  
 carotenoids, 985  
 Caruana, P. *see* Annibale, B.  
 Caruana, P. *see* Lahner, E.  
 carvedilol, 373  
 case-control analysis, 975  
 case-control study, 497  
 case-crossover study, 875  
 Casetti, T. *see* Rizzello, F.  
 Caspary, W.F. *see* Braden, B.  
 Castell, D.O. *see* Tutuian, R.  
 Castellano, E. *see* Barabino, A.  
 Castiella, A. *see* Elizalde, J.I.  
 Castiglione, G.N. *see* Rizzello, F.  
 Castro, A. *see* Moreno-Monteagudo, J.A.  
 Castro, M. *see* Barabino, A.  
 Cazzato, I.A. *see* Armuzzi, A.  
 celecoxib, 819  
 cell division, 633  
 cell proliferation, 633  
 CEM cells, 1021  
 Chan, A.O.O. *see* Wong, W.-M.  
 Chan, C.K. *see* Hung, W.K.  
 Chan, C.K. *see* Wong, W.-M.  
 Chan, C.K. *see* Wong, W.M.  
 Chan, C.K. *see* Xia, H.H.-X.  
 Chan, F.K.L. *see* Wu, J.C.Y.  
 Chan, F.K.L. *see* You, J.H.S.  
 Chan, H.L.Y. *see* Cheng, A.S.L.  
 Chan, K.A. *see* Chang, C.H.  
 Chan, T.Y.K. *see* You, J.H.S.  
 Chang, C.H., Chen, K.Y., Lai, M.Y. & Chan, K.A. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C, 1623  
 Chang, C.S. *see* Poon, S.K.  
 Chang, F.-Y. *see* Luo, J.-C.  
 Chang, K.K. *see* Yee, Y.K.  
 Chang, L. *see* Mayer, E.A.  
 Chapman, M.A.S. *see* Hulin, S.J.  
 Chapman, R.W. *see* Mitchell, S.A.  
 Chasen, R. *see* Rex, D.K.  
 Chaussade, S. *see* Abitbol, V.  
 Chayama, K. *see* Ito, M.  
 Chen, C.L., Orr, W.C., Verlinden, M.H., Dettmer, A., Brinkhoff, H., Riff, D., Schwartz, S., Soloway, R.D., Krause, R., Lanza, F. & Mack, R.J. Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease, 749  
 Chen, C.-Y. *see* Luo, J.-C.  
 Chen, G.H. *see* Poon, S.K.  
 Chen, J.-H. *see* Sheu, B.-S.  
 Chen, K.Y. *see* Chang, C.H.  
 Chen, T.-K. *see* Liao, C.-C.  
 Chen, W.H. *see* Wong, W.-M.  
 Cheng, A.S.L., Chan, H.L.Y., Leung, N.W.Y., Liew, C.T., To, K.F., Lai, P.B.S. & Sung, J.J.Y. Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy, 251  
 Cheng, C.S. *see* Ng, F.H.  
 Cheung, H.K.L. *see* Xia, H.H.-X.  
 Chey, W.D. *see* Ladabaum, U.  
 Chi, C.-H. *see* Sheu, B.-S.  
 Chiang, T.-C. *see* Liao, C.-C.  
 Chiarbonello, B. *see* Giannini, E.  
 children, 951, 1125, 1503, 1663, 2073  
 Chinese, 465, 521, 2037  
 Chinn, D. *see* Rubin, G.  
 Chiodo, F. *see* Manfredi, R.  
 Chiu, Y.-L. *see* Huang, J.-Q.  
 Choi, I.J., Jung, H.C., Choi, K.W., Kim, J.H., Ahn, D.S., Yang, U.S., Rew, J.S., Lee, S.I., Rhee, J.C., Sik Chung, I., Chung, J.M. & Hong, W.-S. Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for *Helicobacter pylori* eradication, 145  
 Choi, I.J. *see* Kim, J.S.  
 Choi, K.W. *see* Choi, I.J.  
 cholesterol, 577  
 Christensen, E. *see* Schiodt, F.V.

- chromogranin A, 1367  
 chronic, 1623, 1633  
 chronic hepatitis B, 251  
 chronic hepatitis C, 243, 1091, 1555  
 chronic hepatitis, 717  
 chronic liver disease, 361  
 chronic pancreatitis, 2097  
 Chrysos, E. *see* Athanasakis, E.  
 Chung, J.M. *see* Choi, I.J.  
 ciclosporin, 181, 1021, 1503, 2061  
 Ciociola, A.A. *see* Gardner, J.D.  
 Ciociola, A.A. *see* Orenstein, S.R.  
 Ciociola, A.A. *see* Robinson, M.  
 ciprofloxacin, 909  
 cirrhosis, 985  
 cisapride, 297, 743, 951, 1641  
 clarithromycin, 137, 145, 569, 793, 1047  
 clarithromycin resistance, 1933, 2073  
 Claversal Foam, 415  
 Clemens, C.H.M., Samsom, M., Van Berge Henegouwen, G.P.,  
     Fabri, M. & Smout, A.J.P.M. Effect of alosetron on left colonic  
     motility in non-constipated patients with irritable bowel  
     syndrome and healthy volunteers, 993  
 Clinard, F. *see* Faivre-Finn, C.  
 clinical practice, 487  
 clinical remission, 1233  
 clinical trial, 1327  
 clonidine, 945  
 Coakley, A.J. *see* Lamb, E.J.  
 Coccia, G. *see* Bortolotti, M.  
 coeliac disease, 1333  
 Cohen, A.F. *see* Kamerling, I.M.C.  
 Cohen, R.D. The quality of life in patients with Crohn's disease,  
     1603  
 Colin, R. for the HEPYLOG Investigator Study Group. Duodenal  
     ulcer healing with 1-week eradication triple therapy followed,  
     or not, by anti-secretory treatment: a multicentre double-blind  
     placebo-controlled trial, 1157  
 colitis, 181  
 Colle, I. *see* Van Vlierberghe, H.  
 Collings, K.L., Rodriguez-Stanley, S., Proskin, H.M., Robinson, M.  
     & Miner Jr, P.B. Clinical effectiveness of a new antacid chewing  
     gum on heartburn and oesophageal pH control, 2029  
 colon, 603  
 colon carcinoma, 353  
 colon transit, 1781  
 colonic delivery, 1771  
 colonic fluid absorption, 623  
 colonic motility, 623, 985  
 colonic transit constipation, 759  
 colonic transit time, 587  
 colonoscopy, 937, 1197, 1327  
 colorectal cancer, 333, 1197, 1225  
 combined treatment, 243  
 complementary therapy, 197  
 complications, 27, 1547  
 concanavalin-A, 633  
 Conio, M. *see* Zentilin, P.  
 constipation, 1701  
 constipation, 603  
 contrast agent, 217  
 controlled trial, 27, 1649  
 Cooney, R. *see* Sengupta, S.  
 Corazzi, A. *see* Ortiz, R.A.M.  
 corpus gastritis, 887  
 Corrado, G. *see* Franzese, A.  
 Correa, P. *see* Rugge, M.  
 corticosteroids, 647, 1241, 1519, 1939  
 cortisol, 1021  
 Cosme, A. *see* Elizalde, J.I.  
 cost analysis, 1529, 2089  
 cost-effectiveness, 1469  
 cost-effectiveness analysis, 41  
 cost-minimization analysis, 1491  
 costs, 1217  
 co-twin control analysis, 975  
 Coulshed, D.S. *see* Eslick, G.D.  
 COX activity, 847  
 COX-2 inhibitor, 847  
 Crafa, P. *see* Bashir, S.  
 Cremonini, F., Di Caro, S., Nista, E.C., Bartolozzi, F., Capelli, G.,  
     Gasbarrini, G. & Gasbarrini, A. Meta-analysis: the effect of  
     probiotic administration on antibiotic-associated diarrhoea,  
     1461  
 Cremonini, F., Mullan, B.P., Camilleri, M., Burton, D.D. & Rank,  
     M.R. Performance characteristics of scintigraphic transit  
     measurements for studies of experimental therapies, 1781  
 Cremonini, F. *see* Armuzzi, A.  
 Cremonini, F. *see* Di Caro, S.  
 Crispino, P. *see* Paoluzi, O.A.  
 Crocellà, L. *see* Della Monica, P.  
 Crocombe, W. *see* Mason, J.  
 Crohn's disease, 51, 79, 399, 693, 857, 919, 1101, 1117, 1225,  
     1509, 1519, 1579, 1603, 1743, 1761, 1895, 1903  
 Cronkhite-Canada syndrome, 333  
 crypt branching, 633  
 crypt fission, 633  
 Csef, H. *see* Kraus, M.R.  
 Cucchiara, S. *see* Barabino, A.  
 Cucchiara, S. *see* Franzese, A.  
 Cuillerier, E. *see* Marteau, P.  
 Cunliffe, R.N. & Scott, B.B. Review article: monitoring for drug  
     side-effects in inflammatory bowel disease, 647  
 C-urea breath test, 787  
 Curran, R. *see* Massironi, S.  
 cyclo-oxygenase, 847  
 cyclo-oxygenase-2, 251  
 cyclo-oxygenase-2 inhibitor, 2089  
 CYP2C19 extensive metabolizer, 1811  
 CYP2C19 genotype, 837  
 cytokines, 399  
 cytosolic hepatic function, 1977  
 Dalhoff, K. *see* Schmidt, L.E.  
 D'Alincourt, A. *see* Gournay, J.

- Dalke, D. *see* Yacyshyn, B.R.  
 Dalmau, B. *see* Calvet, X.  
 D'Ambra, G. *see* Lahner, E.  
 D'Arienzo, A. *see* Rizzello, F.  
 Dawson, C. *see* Langmead, L.  
 Day, A. *see* Shaw, I.S.  
 De Angelis, C. *see* Caletti, G.  
 De Argila, C.M. *see* Elizalde, J.I.  
 De Block, C.E.M., De Leeuw, I.H., Bogers, J.J.P.M., Pelckmans, P.A., Ieven, M.M., Van Marck, E.A.E., Van Hoof, V., Máday, E., Van Acker, K.L. & Van Gaal, L.F. *Helicobacter pylori*, parietal cell antibodies and autoimmune gastropathy in type 1 diabetes mellitus, 281  
 De Boer, W.A. *see* Laheij, R.J.F.  
 De Giacomo, C. *see* Barabino, A.  
 De Hoon, J.N. *see* Van Hecken, A.  
 de Jong-van den Berg, L.T.W. *see* Klok, R.M.  
 de Lalla, F. *see* Fabris, P.  
 De Leeuw, I.H. *see* De Block, C.E.M.  
 De Lepeleire, I. *see* Van Hecken, A.  
 De Lorenzo, A. *see* Armuzzi, A.  
 De Luca, I. *see* Bazzoli, F.  
 De Micheli, E. *see* Frazzoni, M.  
 De Pauw, M. *see* Sloots, C.E.J.  
 De Pedro, A. *see* Moreno-Montegudo, J.A.  
 De Ponti, F., Netzer, R., DeGiorgio, M.C., Bateson, H.K., Parsons, P. & Inauen, W. Letters to the Editors, 643  
 De Schryver, A.M.P., Andriess, G.I., Samsom, M., Smout, A.J.P.M., Gooszen, H.G. & Akkermans, L.M.A. The effects of the specific 5HT<sub>4</sub> receptor agonist, prucalopride, on colonic motility in healthy volunteers, 603  
 De Sena, R. *see* Gaeta, G.B.  
 De Souza, C.A.F. *see* Ortiz, R.A.M.  
 De Vos, M. *see* Van Vlierberghe, H.  
 de'Angelis, G.L. *see* Barabino, A.  
 decision analysis, 41, 727, 1003  
 decision tree, 2089  
 Defarges, V. *see* Boixeda, D.  
 Deguer, M. *see* Ortiz, R.A.M.  
 Delanghe, J. *see* Van Vlierberghe, H.  
 Della Monica, P., Lavagna, A., Masoero, G., Lombardo, L., Crocellá, L. & Pera, A. Effectiveness of *Helicobacter pylori* eradication treatments in a primary care setting in Italy, 1269  
 Delle Fave, G. *see* Annibale, B.  
 Delle Fave, G. *see* Lahner, E.  
 Demetriou, A.A. *see* Pazzi, P.  
 Dent, J. *see* Mallertheiner, P.  
 Depré, M. *see* Van Hecken, A.  
 depression, 1091  
 Derbyshire, S.W.G. *see* Mayer, E.A.  
 Desager, J.P. *see* Dewit, O.  
 Dettmer, A. *see* Chen, C.L.  
 Devault, K. *see* Kovacs, T.O.G.  
 development, 799  
 Dewit, O., Vanheuverzwyn, R., Desager, J.P. & Horsmans, Y. Interaction between azathioprine and aminosaliclates: an *in vivo* study in patients with Crohn's disease, 79  
 Dhillon, A.P. *see* Gordon, F.H.  
 Dhir, V. *see* Laine, L.  
 Di Caro, S., Ojetti, V., Zocco, M.A., Cremonini, F., Bartolozzi, F., Candelli, M., Lupascu, A., Nista, E.C., Cammarota, G. & Gasbarrini, A. Mono, dual and triple moxifloxacin-based therapies for *Helicobacter pylori* eradication, 527  
 Di Caro, S. *see* Cremonini, F.  
 Di Giulio, E. *see* Annibale, B.  
 Di Giulio, E. *see* Lahner, E.  
 Di Martino, V. *see* Goulenok, C.  
 Di Matteo, G. *see* Rizzello, F.  
 Di Nardo, G. *see* Franzese, A.  
 Di Pietro, C. *see* Bazzoli, F.  
 diabetes, 281, 951  
 diabetic gastropathy, 945  
 diagnosis, 683, 813, 1407, 1443  
 diagnosis and eradication, 533  
 diagnostic, 1283  
 diagnostic accuracy, 787  
 diarrhoea, 595, 769, 1461, 1709  
 diclofenac, 819  
 distal ulcerative colitis, 415  
 Distrutti, E., Fiorucci, S., Hauer, S.K., Pensi, M.O., Vanasia, M. & Morelli, A. Effect of acute and chronic levosulpride administration on gastric tone and perception in functional dyspepsia, 613  
 Dito, L. *see* Franzese, A.  
 Dixon, M.F. *see* Rugge, M.  
 Doldán, I. *see* Sambuelli, A.  
 Domareva, I. *see* Isakov, V.  
 Domènech, E., Garcia-Planella, E., Bernal, I., Rosinach, M., Cabré, E., Fluvà, L., Boix, J. & Gassull, M.A. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis, 2061  
 domperidone, 951  
 Domschke, W. *see* Ullerich, H.  
 Donoghue, S. *see* Gordon, F.H.  
 Dorn, G.H. *see* Ofman, J.J.  
 Dorr, F.A. *see* Yacyshyn, B.R.  
 double blind, 27  
 Draganov, V. *see* Tankova, L.  
 drug development, 343  
 drug interaction, 79, 1539  
 drug monitoring, 2053  
 drug therapy, 27  
 Drummond, M. *see* Mason, J.  
 Ducons, J. *see* Calvet, X.  
 Duffett, S. *see* Mason, J.  
 Dulbecco, P. *see* Bilardi, C.  
 Dulbecco, P. *see* Zentilin, P.  
 Duley, J. *see* Ansari, A.  
 duodenal disorders, 799, 1209, 1955  
 duodenal ulcer scar, 275  
 duodenal ulcer, 1137, 1157, 1431  
 duodenal ulcer, 275, 303, 779  
 Dupas, B. *see* Gournay, J.



- Dupas, J.-L. *see* Abitbol, V.  
Dwarakanath, A.D. *see* Rubin, G.  
DXA, 1519  
Dynder, A. *see* Van Hecken, A.  
dysentery, 1709  
dyspepsia, 105, 819, 1075, 1491, 1709, 2081
- Earnest, D.L. *see* Tougas, G.  
Ebert, M.P.A. & Malfertheiner, P. Review article: pathogenesis of sporadic and familial gastric cancer — implications for clinical management and cancer prevention, 1059  
ECL cell hyperplasia, 1367  
economic, 1217, 1469  
effectiveness, 1269  
Eggo, M.C. *see* Hulin, S.J.  
Ehrenpreis, E.D. *see* Ginsburg, P.M.  
Eisen, G.M. *see* Goldstein, J.L.  
elderly, 683  
electrogastrography, 119, 129, 951  
Elizalde, I. *see* Elizalde, J.I.  
Elizalde, J.I., Piqué, J.M., Moreno, V., Morillas, J.D., Elizalde, I., Bujanda, L., De Argila, C.M., Cosme, A., Castiella, A. & Ros, E. (for the Group of Study of Oesophageal, Gastric Diseases from the Spanish Gastroenterological Association). Influence of *Helicobacter pylori* infection and eradication on blood lipids and fibrinogen, 577  
Ell, P.J. *see* Tuleu, C.  
Ellis, C. *see* Tinto, A.  
El-Serag, H.B., Olden, K. & Bjorkman, D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review, 1171  
Emmanuel, A.V., Roy, A.J., Nicholls, T.J. & Kamm, M.A. Prucalopride, a systemic enterokinetic, for the treatment of constipation, 1347  
Emmanuel, A.V. *see* Van Den Bogaerde, J.  
endoscopic ultrasonography, 1715  
enema, 27  
energy-deficiency, 325  
Enghofer, M. *see* Braden, B.  
enteric-coated aspirin, 1683  
enterokinetic, 603, 759  
Entsuaeh, L.K. *see* Bashir, S.  
environmental factors, 975  
epidemiology, 1407, 1519, 1709  
epithelial transport, 1571  
epithelium, 633  
eradication, 153, 515, 1157, 1269, 1431, 1443, 1449, 1457, 2067  
eradication treatment, 507  
ERCP, 727  
Ernst, E. *see* Thompson Coon, J.  
erosive oesophagitis, 445, 2043  
erosive reflux oesophagitis, 735  
erythromycin, 1563  
Eslick, G.D., Coulshed, D.S. & Talley, N.J. Review article: the burden of illness of non-cardiac chest pain, 1217  
Eslick, G.D., Yan, P., Xia, H.H.-X., Murray, H., Spurrett, B. & Talley, N.J. Foetal intrauterine growth restrictions with *Helicobacter pylori* infection, 1677  
esomeprazole, 1301  
essential fatty acids, 1125  
Evans, B.K. *see* Hawkes, N.D.  
Evans, J. *see* Huilgol, V.  
Evenepoel, P. *see* Geboes, K.P.
- Faas, H., Steingoetter, A., Feinle, C., Rades, T., Lengsfeld, H., Boesiger, P., Fried, M. & Schwizer, W. Effects of meal consistency and ingested fluid volume on the intragastric distribution of a drug model in humans—a magnetic resonance imaging study, 217  
Fabri, M. *see* Clemens, C.H.M.  
Fabris, P., Pilotto, A., Bozzola, L., Tositti, G., Solliati, G., Manfrin, V. & de Lalla, F. Serum pepsinogen and gastrin levels in HIV-positive patients: relationship with CD4+ cell count and *Helicobacter pylori* infection, 807  
faecal bile acids, 587  
faecal markers, 675  
Faessel, H.M. *see* Orenstein, S.R.  
failure, 1047  
Faivre, J. *see* Faivre-Finn, C.  
Faivre-Finn, C., Bouvier, A.-M., Mitry, E., Rassiat, E., Clinard, F. & Faivre, J. Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? 353  
Falasco, G., Zincola, R. & Forbes, A. Review article: immunosuppressants in distal ulcerative colitis, 181  
Falk, P. *see* Hart, A.L.  
Faller, H. *see* Kraus, M.R.  
familial, 1059  
famotidine, 837, 1317  
Farrell, R.J., Menconi, M.J., Keates, A.C. & Kelly, C.P. P-Glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes, 1021  
Farthing, M.J.G. *see* Zulu, I.  
Fasciolo, D. *see* Zentilin, P.  
Fasoli, A. *see* Giannini, E.  
Fass, R. *see* Ofman, J.J.  
FAST trial investigation *see* Robinson, M.  
Feagan, B.G. *see* Kane, S.V.  
Feakins, R. *see* Zulu, I.  
Federici, T. *see* Caletti, G.  
Feinle, C. *see* Faas, H.  
Felaco, F.M. *see* Gaeta, G.B.  
Felsenberg, D. *see* Stockbrügger, R.W.  
Felt-Bersma, R.J.F. *see* Sloots, C.E.J.  
Feltbower, R. *see* Mason, J.  
female, 1877  
Fendrick, A.M. *see* Ladabaum, U.  
Fennerty, M.B. *see* Ofman, J.J.  
Ferguson, A. *see* Stockbrügger, R.W.  
fermented milk, 587  
Fernández-Bermejo, M. *see* Moreno-Monteagudo, J.A.  
Ferraro, G. *see* Bashir, S.  
Ferraz, J.G.P. *see* Ortiz, R.A.M.  
Ferreira, I.J. *see* Serrano, P.  
Fevery, J. *see* Van De Casteele, M.

- Feydt-Schmidt, A., Rüssmann, H., Lehn, N., Fischer, A., Antoni, I., Störk, D. & Koletzko, S. Fluorescence *in situ* hybridization vs. epilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant *Helicobacter pylori* strains in gastric biopsies from children, 2073
- fibrinogen, 577
- fibrosis, 717
- Filice, G. *see* Gaeta, G.B.
- Finizia, C. *see* Cange, L.
- Fiocca, R. *see* Rugge, M.
- Fioramonti, J. *see* Picard, C.
- Fiorucci, S. *see* Distrutti, E.
- Fischer, A. *see* Feydt-Schmidt, A.
- FitzGerald, A.J. *see* Sasaki, M.
- Fitzgerald, L. *see* Mayer, E.A.
- Fitzgerald, S. *see* Robinson, M.
- Fleming, T.J. *see* Tremaine, W.J.
- flexible sigmoidoscopy, 1197
- Flockhart, D.A. *see* Marino, G.
- Floyd, D. *see* Khan, Z.
- flumazenil, 361
- fluorescence, 875
- fluorescence *in-situ* hybridization, 2073
- fluoride, 919
- fluoroquinolones, 527
- Fluvià, L. *see* Domènech, E.
- foam enema, 415
- foetal intrauterine growth restriction, 1677
- Fontana, M. *see* Barabino, A.
- food allergens, 1903
- for the HEPYLOG Investigator Study Group. *see* Colin, R.
- Forbes, A. *see* Falasco, G.
- Ford, J. *see* Shaw, I.S.
- Fordtran, J. *see* Högenauer, C.
- Forman, D. *see* Mason, J.
- Fossi, S. *see* Bazzoli, F.
- Foster, R. *see* Poullis, A.
- fractures, 1519
- Frame, M. *see* Hart, A.L.
- Franzese, A., Borrelli, O., Corrado, G., Rea, P., Di Nardo, G., Grandinetti, A.L., Dito, L. & Cucchiara, S. Domperidone is more effective than cisapride in children with diabetic gastroparesis, 951
- Fraser, A.G., Morton, D., McGovern, D., Travis, S. & Jewell, D.P. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease, 693
- Fraser, A.G., Orchard, T.R., Robinson, E.M. & Jewell, D.P. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine, 1225
- Frazzoni, M., De Micheli, E., Grisendi, A. & Savarino, V. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression, 881
- Frazzoni, M., De Micheli, E., Grisendi, A. & Savarino, V. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison, 35
- Freyne, P.J. *see* Mahmud, N.
- Fried, M. *see* Faas, H.
- Fuentes, J. *see* Lanas, A.
- Fujioka, T. *see* Murakami, K.
- Fujishiro, H. *see* Adachi, K.
- Fukushima, Y. *see* Saitoh, T.
- Fumagalli, A. *see* Giannini, E.
- functional constipation, 1347
- functional dyspepsia, 613, 959, 1641, 1805
- Fung, F.M.Y. *see* Hung, W.K.
- Fung, F.M.Y. *see* Wong, W.M.
- Fung, F.M.Y. *see* Xia, H.H.-X.
- Fung, K. *see* Orenstein, S.R.
- Fung, K. *see* Robinson, M.
- furazolidone, 1277
- Furuta, T., Shirai, N., Xiao, F., Takashima, M. & Hanai, H. Effect of *Helicobacter pylori* infection and its eradication on nutrition, 799
- Furuta, T. *see* Shirai, N.
- Fusaroli, P. *see* Caletti, G.
- Futagami, S., Hiratsuka, T., Wada, K., Tatsuguchi, A., Tsukui, T., Miyake, K., Akamatsu, T., Hosone, M., Sakamoto, C. & Kobayashi, M. Inhibition of *Helicobacter pylori*-induced cyclooxygenase-2 aggravates NSAID-caused gastric damage in Mongolian gerbils, 847
- GABA<sub>B</sub>, 869
- gabexate mesilate, 1791
- Gaeta, G.B., Precone, D.F., Felaco, F.M., Bruno, R., Spadaro, A., Stornaiuolo, G., Stanzione, M., Ascione, T., De Sena, R., Campanone, A., Filice, G. & Piccinino, F. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C, 1633
- Gaia, C. *see* Netzer, P.
- gallbladder, 129
- gallbladder volume, 1801
- Galmiche, J.P. *see* Gournay, J.
- Gambaro, C. *see* Bilardi, C.
- Gambaro, C. *see* Zentilin, P.
- gamma scintigraphy, 1771
- Gandullia, P. *see* Barabino, A.
- Ganskaya, Z. *see* Isakov, V.
- García-Buey, L. *see* Moreno-Montegudo, J.A.
- García-Plaza, A. *see* Boixeda, D.
- García-Planella, E. *see* Domènech, E.
- Gardner, J.D., Ciociola, A.A., Robinson, M. & McIsaac, R.L. Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity, 1317
- Gardner, J.D., Perdomo, C., Sloan, S., Hahne, W.F., Barth, J.A., Rodriguez-Stanley, S. & Robinson, M. Integrated acidity and rabeprazole pharmacology, 455
- Gardner, J.D., Rodriguez-Stanley, S., Robinson, M. & Miner Jr, P.B. Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease, 1819
- gas, 1641
- Gasbarrini, A. *see* Armuzzi, A.
- Gasbarrini, A. *see* Cremonini, F.
- Gasbarrini, A. *see* Di Caro, S.



- Gasbarrini, G. *see* Armuzzi, A.  
 Gasbarrini, G. *see* Cremonini, F.  
 Gaspari, M. *see* Yacyshyn, B.R.  
 Gasperi, V. *see* Perri, F.  
 Gassull, M.A. *see* Domènech, E.  
 gastric, 799  
 gastric acidity, 875  
 gastric cancer, 1059  
 gastric carcinoid, 1367  
 gastric disorder, 1209, 1955  
 gastric emptying, 119, 945, 1341, 1481, 1563  
 gastric mucosal atrophy, 1249  
 gastric outlet obstruction, 1203  
 gastric perception, 613  
 gastric pH, 875  
 gastric ulcer, 779, 1137, 1431  
 gastric ultrasound, 951  
 gastrin, 303, 799, 1723, 1805  
 gastritis, 159  
 gastritis, 1923  
 gastroduodenal motility, 1563  
 gastrointestinal, 1059, 1781  
 gastrointestinal bleeding, 779, 2037  
 gastrointestinal disorders, 969  
 gastrointestinal endoscopy, 1003  
 gastrointestinal haemorrhage, 1945  
 gastrointestinal haemostasis, 1003  
 gastrointestinal hormones, 119  
 gastrointestinal oncology, 1197  
 gastrointestinal oncology, 1209, 1843  
 gastrointestinal tract, 633  
 gastro-oesophageal reflux disease, 17, 261, 435, 473, 479, 545, 735, 743, 749, 819, 869, 899, 1143, 1309, 1469, 1481, 1655, 1795, 2029, 2043  
 gastroparesis, 1341  
 gastroscopy, 1011  
 Gatta, L. *see* Palli, D.  
 Gavin, M.W. *see* Sonnenberg, A.  
 Geboes, K.P., Maes, B., Luybaerts, A., Evenepoel, P., Rutgeerts, P., Ghos, Y. & Geypens, B. Magnesium chloride slows gastric emptying, but does not affect digestive functions, 1571  
 Geis, G.S. *see* Goldstein, J.L.  
 Gendre, J.P. *see* Abitbol, V.  
 gene, 1059  
 general practice, 1067  
 genetic and familial-environmental effects, 975  
 genetic counselling, 1843  
 genetic testing, 1843  
 Genta, R.M. *see* Ruge, M.  
 Georgopoulos, S.D., Ladas, S.D., Karatapanis, S., Triantafyllou, K., Spiliadi, C., Mentis, A., Artakis, V. & Raptis, S.A. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, *Helicobacter pylori* eradication therapies, 569  
 Gerhardt, M.F. *see* Marteau, P.  
 Gertz, B. *see* Malchow, H.  
 Geypens, B. *see* Geboes, K.P.  
 Ghati, M.A. *see* Sasaki, M.  
 Ghos, Y. *see* Geboes, K.P.  
 Ghosh, S. *see* Arnott, I.D.R.  
 Ghosh, S. *see* Campbell, S.  
 Ghosh, S. *see* Khan, Z.  
 Gialler, M.H. *see* Mansfield, J.C.  
 Giannini, E., Fasoli, A., Chiarbonello, B., Malfatti, F., Romagnoli, P., Botta, F., Testa, E., Polegato, S., Fumagalli, A. & Testa, R. <sup>13</sup>C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection, 717  
 Giardiello, F.M. *see* Trimbath, J.D.  
 Gibril, F. *see* Bashir, S.  
 Gibson, J.A. *see* Green, J.R.B.  
 Gil, A. *see* Sambuelli, A.  
 Gil, M. *see* Calvet, X.  
 Ginsburg, P.M. & Ehrenpreis, E.D. A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis, 2115  
 Gionchetti, P. *see* Mimura, T.  
 Gionchetti, P. *see* Rizzello, F.  
 Gisbert, J.P. *see* Vallve, M.  
 Gisbert, J.P. & Pajares, J.M. Review article: *Helicobacter pylori* 'rescue' regimen when proton pump inhibitor-based triple therapies fail, 1047  
 Gisbert, J.P. & Pajares, J.M. Review article: *Helicobacter pylori* infection and gastric outlet obstruction — prevalence of the infection and role of antimicrobial treatment, 1203  
 Gissi, A. *see* Barabino, A.  
 Glebas, K. *see* Novick, J.  
 glidomorphine, 663  
 Glise, H. *see* Hart, A.L.  
 glucagons, 111  
 gluten-free diet, 1333  
 Goff, J. *see* Yacyshyn, B.R.  
 Goldstein, J.L., Eisen, G.M., Burke, T.A., Peña, B.M., Lefkowitz, J. & Geis, G.S. Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac, 819  
 Goldwater, D.R. *see* Huang, J.-Q.  
 Gonzalez, O. *see* Sambuelli, A.  
 Goodlad, R.A. *see* Sasaki, M.  
 Gooszen, H.G. *see* De Schryver, A.M.P.  
 Gorard, D.A. *see* Bhat, K.  
 Gordon, F.H., Hamilton, M.L., Donoghue, S., Greenlees, C., Palmer, T., Rowley-Jones, D., Dhillon, A.P., Amlot, P.L. & Pounder, R.E. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin, 699  
 Gottesdiener, K. *see* Van Hecken, A.  
 Goulonok, C., Bernard, B., Cadranet, J.F., Thabut, D., Di Martino, V., Opolon, P. & Poynard, T. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis, 361  
 Gournay, J., Tchuente, J., Richou, C., Masliah, C., Lerat, F., Dupas, B., Martin, T., Nouel, J.F., Schnee, M., Montigny, P., D'Alincourt, A., Hamy, A., Paineau, J., Le Néel, J.-C., Le Borgne, J. & Galmiche, J.P. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis, 1529  
 Graffner, H. *see* Hart, A.L.  
 Graffner, H. *see* Stockbrügger, R.W.

- Graham, D.Y. *see* Mallertheiner, P.  
 Graham, D.Y. *see* Verghese, V.J.  
 Granato, A. *see* Pazzi, P.  
 Grandinetti, A.L. *see* Franzese, A.  
*granisetron*, 623  
 Grant, C. *see* Hallert, C.  
 Grant, G. *see* Sasaki, M.  
 Graziano, A. *see* Sambuelli, A.  
 Green, J.R.B., Mansfield, J.C., Gibson, J.A., Kerr, G.D. & Thornton, P.C. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis, 61  
 Green, L. *see* Rubin, G.  
 Greenlees, C. *see* Gordon, F.H.  
 Grehn, S. *see* Hallert, C.  
 Grieco, A. *see* Armuzzi, A.  
 Griffiths, N.M. *see* Picard, C.  
 Grimaud, J.C. *see* Marteau, P.  
 Grisendi, A. *see* Frazzoni, M.  
 Grännö, C. *see* Hallert, C.  
 Grossi, C. *see* Lahner, E.  
 Grossi, G. *see* Bortolotti, M.  
 Group of Study of Oesophageal, Gastric Diseases from the Spanish Gastroenterological Association. *see* Elizalde, J.I.  
*growth*, 799  
*growth factors*, 1917  
*growth retardation*, 1677  
 Grunow, J.E. *see* Orenstein, S.R.  
 Gschossmann, J. *see* Holtmann, G.  
 Gu, Q. *see* Wong, W.M.  
 Guagnozzi, D. *see* Caprilli, R.  
 Guardiola, J. *see* Calvet, X.  
 Guillén, F. *see* San Miguel, R.  
 Guirao, R. *see* Calvet, X.  
*gut flora*, 1383  
*gut inflammation*, 2017  
*gut transit*, 1347  
*H<sub>2</sub>-receptor antagonists*, 1137, 1805  
 Haapiainen, R. *see* Kokkola, A.  
*haemochromatosis*, 1963  
 Hahne, W.F. *see* Gardner, J.D.  
 Hallerbäck, B., Bommelaer, G., Bredberg, E., Campbell, M., Hellblom, M., Lauritsen, K., Wienbeck, M. & Holmgren, L.-L. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study, 959  
 Hallert, C., Grant, C., Grehn, S., Grännö, C., Hultén, S., Midhagen, G., Ström, M., Svensson, H. & Valdimarsson, T. Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years, 1333  
 Hamelin, B. *see* Svedberg, P.  
 Hamilton, M.I. *see* Gordon, F.H.  
 Hamm, L. *see* Mayer, E.A.  
 Hamy, A. *see* Gournay, J.  
 Hanai, H. *see* Furuta, T.  
 Hanai, H. *see* Shirai, N.  
 Hanauer, S.B. *see* Sytgat, G.N.J.  
 Harper, A. *see* Bhat, K.  
 Hart, A. & Kamm, M.A. Review article: mechanisms of initiation and perpetuation of gut inflammation by stress, 2017  
 Hart, A.L., Stagg, A.J., Frame, M., Graffner, H., Glise, H., Falk, P. & Kamm, M.A. Review article: the role of the gut flora in health and disease, and its modification as therapy, 1383  
 Haruma, K. *see* Ito, M.  
 Hashimoto, T., Adachi, K., Ishimura, N., Hirakawa, K., Katsube, T., Kurotani, A., Hattori, S. & Kinoshita, Y. Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy—a comparative study with butyl scopolamine bromide, 111  
 Hassan, C. *see* Ansari, A.  
 Hattori, S. *see* Hashimoto, T.  
 Hattori, T. *see* Rugge, M.  
 Hauer, S.K. *see* Distrutti, E.  
 Hawkes, N.D., Rhodes, J., Evans, B.K., Rhodes, P., Hawthorne, A.B. & Thomas, G.A.O. Naloxone treatment for irritable bowel syndrome — a randomized controlled trial with an oral formulation, 1649  
 Hawkey, C.J. *see* Stack, W.A.  
 Hawkey, G.M. *see* Stack, W.A.  
 Hawkins, C. *see* Langmead, L.  
 Hawthorne, A.B. *see* Hawkes, N.D.  
 Hayashi, P.H. & Trotter, J.F. Review article: adult-to-adult right hepatic lobe living donor liver transplantation, 1833  
 Hayes, P.C. *see* Tripathi, D.  
 Heading, R.C. *see* Camilleri, M.  
*healing*, 1157  
*health*, 1469  
*health economics*, 559  
*health status*, 1101  
*health-care seeking behaviour*, 1217  
*health-related quality of life*, 1101  
*health-seeking behaviour*, 2081  
*healthy volunteers*, 819  
 Hearing, S.D. *see* Shaw, I.S.  
*heartburn*, 435, 479, 899, 1309, 1431, 1819, 2029  
 Hegedus, R. *see* Robinson, M.  
*Helicobacter pylori* therapy, 1143  
*Helicobacter pylori*, 105, 137, 145, 153, 159, 167, 275, 281, 291, 315, 487, 497, 507, 515, 521, 527, 533, 545, 559, 569, 577, 683, 779, 787, 793, 799, 813, 847, 887, 1015, 1037, 1047, 1059, 1143, 1149, 1163, 1203, 1241, 1261, 1269, 1277, 1283, 1291, 1301, 1431, 1443, 1449, 1457, 1663, 1677, 1669, 1715, 1723, 1733, 1805, 1933, 2067, 2073  
 Hellblom, M. *see* Hallerbäck, B.  
 Hellman, R.S. *see* Huilgol, V.  
 Helwig, U. *see* Mimura, T.  
*hepapoietin*, 235  
*hepatic encephalopathy*, 361  
*hepatic resection*, 1529  
*hepatic venous pressure gradient*, 373  
*hepatitis C virus*, 717  
*hepatitis C*, 381, 1611, 1623, 1633, 2107  
*hepatocellular*, 1  
*hepatocellular carcinoma*, 251, 1529

- hepatocyte growth factor, 235
- herbal medicine, 1689
- herbal therapies, 197
- hereditary, 1059
- hereditary colorectal cancer, 1843
- Hernández-Ranz, F. *see* Boixeda, D.
- HFE, 1963
- Högenauer, C., Aichbichler, B., Santa Ana, C., Porter, J. & Fordtran, J. Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum *in vivo*, 769
- HHC, 1963
- hiatal hernia, 881
- high amplitude propagated contraction, 985
- Higham, J. *see* Kang, J.-Y.
- high-dose interferon- $\alpha$ , 2107
- highly active antiretroviral therapy (HAART), 1791
- Hirakawa, J. *see* Saitoh, T.
- Hirakawa, K. *see* Hashimoto, T.
- Hiratsuka, T. *see* Futagami, S.
- Hirohata, Y. *see* Yoshikawa, I.
- Hirsch, D.P., Tytgat, G.N.J. & Boeckstaens, G.E.E. Review article: transient lower oesophageal sphincter relaxations—a pharmacological target for gastro-oesophageal reflux disease? 17
- Hirschowitz, B.L., Simmons, J. & Mohnen, J. Minor effects of *Helicobacter pylori* on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors, 303
- histamine 2 receptor antagonists, 473
- histamine-metabolite, 1367
- HIV, 799
- HIV infection, 1791
- Ho, V.Y.K. *see* Hung, W.K.
- Hodgson, H.J.F. *see* Aisowmely, A.M.
- Hofer, T. *see* Kane, S.V.
- Hojo, M., Miwa, H., Ohkusa, T., Ohkura, R., Kurosawa, A. & Sato, N. Alteration of histological gastritis after cure of *Helicobacter pylori* infection, 1923
- Holdsworth, C.D. *see* Mansfield, J.C.
- Holman, R. *see* Kuiken, S.D.
- Holmgren, L.-L. *see* Hallerbäck, B.
- Holt, M.P. *see* Khan, Z.
- Holtmann, G., Bytzer, P., Metz, M., Loeffler, V. & Blum, A.L. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease, 479
- Holtmann, G., Gschossmann, J., Mayr, P. & Talley, N.J. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia, 1641
- Holton, J. *see* Palli, D.
- homocysteine, 1333
- Hong, W.-S. *see* Choi, I.J.
- Horsmans, Y. *see* Dewit, O.
- Hosone, M. *see* Futagami, S.
- hospital admissions, 2097
- Howden, C.W. *see* Levine, J.E.
- HPO, 235
- HpSA, 1733
- Härkönen, M. *see* Kokkola, A.
- Hu, W.H.C., Wong, W.-M., Lam, C.L.K., Lam, K.F., Hui, W.M., Lai, K.C., Xia, H.X.H., Lam, S.K. & Wong, B.C.Y. Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study, 2081
- Hu, W.H.C. *see* Hung, W.K.
- Hu, W.H.C. *see* Wong, W.-M.
- Hu, W.H.C. *see* Wong, W.M.
- Hu, W.H.C. *see* Xia, H.H.X.
- Huang, C.-C. *see* Sheu, B.-S.
- Huang, J.-Q., Goldwater, D.R., Thomson, A.B.R., Appelman, S.A., Sridhar, S., James, C.F., Chiu, Y.-L., Pilmer, B.L., Keith, R.G. & Hunt, R.H. Acid suppression in healthy subjects following lansoprazole or pantoprazole, 425
- Huang, S.-H. *see* Liao, C.-C.
- Huornos, S. *see* Sambuelli, A.
- Hui, C.-K., Lai, K.-C., Yuen, M.-F., Wong, W.-M., Lam, S.-K. & Lai, C.-L. Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding? 929
- Hui, C.K. *see* Wong, W.-M.
- Hui, W.M. *see* Hu, W.H.C.
- Hui, W.M. *see* Wong, W.-M.
- Huigol, V., Evans, J., Hellman, R.S. & Soergel, K.H. Acute effect of clonidine on gastric emptying in patients with diabetic gastropathy and controls, 945
- Hulin, S.J., Singh, S., Chapman, M.A.S., Allan, A., Langman, M.J.S. & Eggo, M.C. Sulphide-induced energy deficiency in colonic cells is prevented by glucose but not by butyrate, 325
- Hultén, S. *see* Hallert, C.
- Hung, W.K., Wong, W.M., Wong, G.S.W., Yip, A.W.C., Szeto, M.L., Lai, K.C., Hu, W.H.C., Chan, C.K., Xia, H.H.X., Yuen, M.F., Fung, F.M.Y., Tong, T.S.M., Ho, V.Y.K., Lam, S.K. & Wong, B.C.Y. One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of *Helicobacter pylori* infection in Chinese, 2067
- Hungin, A.P.S. *see* Malfertheiner, P.
- Hungin, A.P.S. *see* Rubin, G.
- Hunt, R.H. *see* Huang, J.-Q.
- Hunter, J.O. *see* Middleton, S.J.
- Hurwitz, A. *see* Passaro, D.J.
- hydroxypropylmethyl cellulose capsules, 1771
- hypergastrinaemia, 1367
- hyperplastic polyposis, 333
- Iacopini, F. *see* Paoluzi, O.A.
- Iannoni, C. *see* Paoluzi, O.A.
- IBDQ, 1101
- ICAM-1, 1761
- Ieven, M.M. *see* De Block, C.E.M.
- Iiritano, E. *see* Bilardi, C.
- Iiritano, E. *see* Zentilin, P.
- ileal pouch, 27
- Imbesi, V. *see* Parente, F.

- immunoassay, 1723  
 immunosuppressants, 1751  
 immunosuppression, 1939  
 Inauen, W. see De Ponti, F.  
 Inauen, W. see Netzer, P.  
 induction, 381  
 induction dosing, 2107  
 infection, 1037  
 inflammation, 1917, 2115  
 inflammatory bowel disease,  
 inflammatory bowel disease, 197, 389, 647, 675, 919, 1125,  
 1503, 1579, 1743, 1895, 1997, 2053, 2061  
 inflammatory disorders, 1509, 1831  
 inflammatory polyposis, 333  
 infliximab, 1101, 1117, 1579  
 inguinal hernia, 1197  
 integrated gastric acidity, 1819  
 integrated oesophageal acidity, 1819  
 interferon, 381, 1611  
 interferon- $\alpha$ , 1091, 1633  
 interferon- $\beta$ , 1233  
 interferon- $\alpha$ -2b, 243  
 interleukin-11, 399  
 intestinal disorders, 1171, 1509  
 intestinal epithelium, 1021  
 intestinal metaplasia, 1449, 1923  
 intestinal mucosa, 595  
 intestinal permeability, 663  
 intestinal protozoa, 595  
 intestinal secretion, 769  
 intragastric acidity, 899, 1301, 1317  
 intragastric drug distribution, 217  
 intragastric pH monitoring, 819  
 intragastric pH, 425, 837, 1811  
 intra-oesophageal pH, 435  
 intra-uterine growth restriction, 1677  
 irritable bowel syndrome, 343, 975, 985, 1187, 1395, 1407,  
 1649, 1701, 1877, 2081  
 Isakov, V., Domareva, I., Koudryavtseva, L., Maev, I. & Ganskaya,  
 Z. Furazolidone-based triple 'rescue therapy' vs. quadruple  
 'rescue therapy' for the eradication of *Helicobacter pylori*  
 resistant to metronidazole, 1277  
 Ishii, H. see Suzuki, M.  
 Ishikawa, T. see Saitoh, T.  
 Ishimura, N. see Hashimoto, T.  
 Ishizaki, T. see Shirai, N.  
 isosorbide mononitrate, 101  
 Israeli, E. see Stockbrügger, R.W.  
 Ito, M., Haruma, K., Kamada, T., Mihara, M., Kim, S.,  
 Kitadai, Y., Sumii, M., Tanaka, S., Yoshihara, M. &  
 Chayama, K. *Helicobacter pylori* eradication therapy  
 improves atrophic gastritis and intestinal metaplasia: a  
 5-year prospective study of patients with atrophic gastritis,  
 1449  
 Jain, S.K. see Spechler, S.J.  
 James, C.F. see Huang, J.-Q.  
 Jansen, J.B.M.J. see Laheij, R.J.F.  
 Jensen, R.T. see Bashir, S.  
 Jewell, D.P. see Fraser, A.G.  
 Jobson, B.A. see Shaw, I.S.  
 Johansson, S. see Svedberg, P.  
 Johnson, E. see Shaw, I.S.  
 Johnson, L.B. see Marino, G.  
 Johnsson, E. see Cange, L.  
 Jokubaitis, L. see Robinson, M.  
 Jones, A. see Malik, A.H.  
 Jones, R. see Kamerling, I.M.C.  
 Jones, R. see Malfertheiner, P.  
 Joslyn, A. see Sytgat, G.N.J.  
 Juliano, M.L. see Van Hecken, A.  
 Jung, H.C. see Choi, I.J.  
 Jung, H.C. see Kim, J.S.  
 Kadyan, H. see Tankova, L.  
 Kagawa, J. see Murakami, K.  
 Kahl, S. see Peitz, U.  
 Kajimura, M. see Shirai, N.  
 Kamada, T. see Ito, M.  
 Kamerling, I.M.C., Van Haarst, A.D., Burggraaf, J., Schoemaker,  
 H.C., Biemond, I., Jones, R., Cohen, A.F. & Masclee, A.A.A.  
 Dose-related effects of motilin on proximal gastrointestinal  
 motility, 129  
 Kamm, M.A. see Emmanuel, A.V.  
 Kamm, M.A. see Hart, A.  
 Kamm, M.A. see Hart, A.L.  
 Kamm, M.A. see Mimura, T.  
 Kamm, M.A. see Van Den Bogaerde, J.  
 Kamm, M.A. Review article: the complexity of drug development  
 for irritable bowel syndrome, 343  
 Kanagawa, K. see Yoshikawa, I.  
 Kane, S.V., Schoenfeld, P., Sandborn, W.J., Tremaine, W., Hofer,  
 T. & Feagan, B.G. Systematic review: the effectiveness of  
 budesonide therapy for Crohn's disease, 1509  
 Kang, J.-Y., Tinto, A., Higham, J. & Majeed, A. Peptic  
 ulceration in general practice in England and Wales  
 1994-98: period prevalence and drug management,  
 1067  
 Kang, J.-Y. see Tinto, A.  
 Kao, A.-W. see Sheu, B.-S.  
 Karatapanis, S. see Georgopoulos, S.D.  
 Karkavitsas, N. see Athanasakis, E.  
 Katsube, T. see Hashimoto, T.  
 Katsube, T. see Saitoh, T.  
 Katz, J.A. see Tremaine, W.J.  
 Katz, P.O. see Tutuian, R.  
 Kawamura, A. see Adachi, K.  
 Keates, A.C. see Farrell, R.J.  
 Keith, R.G. see Huang, J.-Q.  
 Kelleher, D. see Mahmud, N.  
 Kelly, C.P. see Farrell, R.J.  
 Kelly, P. see Zulu, I.  
 Kerr, G.D. see Green, J.R.B.  
 Kerstens, R. see Sloots, C.E.J.

- Khan, Z., MacDonald, C., Wicks, A.C., Holt, M.P., Floyd, D., Ghosh, S., Wright, N.A. & Playford, R.J. Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study, 1917
- Kim, B.G. *see* Kim, J.S.
- Kim, J.H. *see* Choi, I.J.
- Kim, J.S., Kim, S.G., Choi, I.J., Park, M.J., Kim, B.G., Jung, H.C. & Song, I.S. Effect of *Helicobacter pylori* eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer, 275
- Kim, S. *see* Ito, M.
- Kim, S.G. *see* Kim, J.S.
- Kingstone, K. *see* Campbell, S.
- Kinoshita, Y. *see* Adachi, K.
- Kinoshita, Y. *see* Hashimoto, T.
- Kinser, J.A. *see* Netzer, P.
- Kitadai, Y. *see* Ito, M.
- Kitahara, T. *see* Suzuki, M.
- Klok, R.M., Brouwers, J.R.B.J., van den Berg, P.B., de Jong-van den Berg, L.T.W., Tolley, K. & Postma, M.J. Letter to the Editors, 1033
- Kng, C. *see* Ng, F.H.
- Knight, S.C. *see* Van Den Bogaerde, J.
- Koay, E. *see* Lim, L.L.
- Kobayashi, M. *see* Futagami, S.
- Kodama, M. *see* Murakami, K.
- Kogan, Z. *see* Sambuelli, A.
- Kokkola, A., Sipponen, P., Rautelin, H., Härkönen, M., Kosunen, T.U., Haapiainen, R. & Puolakkainen, P. The effect of *Helicobacter pylori* eradication on the natural course of atrophic gastritis with dysplasia, 515
- Koletzko, S. *see* Feydt-Schmidt, A.
- Kong, H.L. *see* Lim, L.L.
- Korn, S. *see* Tutuian, R.
- Kosunen, T.U. *see* Kokkola, A.
- Koudryavtseva, L. *see* Isakov, V.
- Kovacs, T.O.G., Wilcox, C.M., Devault, K., Miska, D., Bochenek, W. & The Pantoprazole US Gerd Study Group B. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study, 2043
- Kowdley, K.V. *see* Whittington, C.A.
- Kraus, M.R., Schäfer, A., Faller, H., Csef, H. & Scheurlen, M. Paroxetine for the treatment of interferon- $\alpha$ -induced depression in chronic hepatitis C, 1091
- Krause, R. *see* Chen, C.L.
- Krause, R. *see* Novick, J.
- Kruidenier, L. & Verspaget, H.W. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous? 1997
- Ksas, B. *see* Picard, C.
- Kuiken, S.D., Lei, A., Tytgat, G.N.J., Holman, R. & Boeckstaens, G.E.E. Effect of the low-affinity, noncompetitive N-methyl-D-aspartate receptor antagonist dextromethorphan on visceral perception in healthy volunteers, 1955
- Kumar, D. *see* Zar, S.
- Kumar, K.S. *see* Malik, A.H.
- Kume, K. *see* Yoshikawa, I.
- Kuo, B., Camilleri, M., Burton, D., Viramontes, B., McKinzie, S., Thomforde, G., O'Connor, M.K. & Brinkmann, B.H. Effects of 5-HT<sub>3</sub> antagonism on postprandial gastric volume and symptoms in humans, 225
- Kuo, P.C. *see* Marino, G.
- Kurosawa, A. *see* Hojo, M.
- Kurotani, A. *see* Hashimoto, T.
- Kurth, M.C. *see* Tremaine, W.J.
- Labenz, J. *see* Peitz, U.
- Lactobacillus*, 1461, 1669
- lactose*, 1591
- Ladabaum, U., Chey, W.D., Scheiman, J.M. & Fendrick, A.M. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis, 1491
- Ladas, S.D. *see* Georgopoulos, S.D.
- Laheij, R.J.F., Van Rossum, L.G.M., De Boer, W.A. & Jansen, J.B.M.J. Corpus gastritis in patients with endoscopic diagnosis of reflux oesophagitis and Barrett's oesophagus, 887
- Lahner, E., Bordi, C., Di Giulio, E., Caruana, P., D'Ambra, G., Milione, M., Grossi, C., Delle Fave, G. & Annibale, B. Role of *Helicobacter pylori* serology in atrophic body gastritis after eradication treatment, 507
- Lahner, E. *see* Annibale, B.
- Lai, C.H. *see* Poon, S.K.
- Lai, C.-L. *see* Hui, C.-K.
- Lai, C.L. *see* Ng, F.H.
- Lai, K.C. *see* Hu, W.H.C.
- Lai, K.-C. *see* Hui, C.-K.
- Lai, K.C. *see* Hung, W.K.
- Lai, K.C. *see* Ng, F.H.
- Lai, K.C. *see* Wong, W.-M.
- Lai, K.C. *see* Wong, W.M.
- Lai, K.C. *see* Xia, H.H.-X.
- Lai, M.Y. *see* Chang, C.H.
- Lai, P.B.S. *see* Cheng, A.S.L.
- Laine, L. & Dhir, V. *Helicobacter pylori* eradication does not worsen quality of life related to reflux symptoms: a prospective trial, 1143
- Lam, C.L.K. *see* Hu, W.H.C.
- Lam, K.F. *see* Hu, W.H.C.
- Lam, S.K. *see* Hu, W.H.C.
- Lam, S.-K. *see* Hui, C.-K.
- Lam, S.K. *see* Hung, W.K.
- Lam, S.K. *see* Ng, F.H.
- Lam, S.K. *see* Wong, W.-M.
- Lam, S.K. *see* Wong, W.M.
- Lam, S.K. *see* Xia, H.H.-X.
- Lamb, E.J., Wong, T., Smith, D.J., Simpson, D.E., Coakley, A.J., Moniz, C. & Muller, A.F. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease, 1895
- lamivudine and interferon treatments*, 251
- Lanas, A., Fuentes, J., Benito, R., Serrano, P., Bajador, E. & Sáinz, R. *Helicobacter pylori* increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin, 779
- Lanas, A. *see* Serrano, P.



- Landgraf, L. *see* Stockbrügger, R.W.  
 Langaker, K.-E. *see* Tougas, G.  
 Langman, M.J.S. *see* Hulin, S.J.  
 Langmead, L., Dawson, C., Hawkins, C., Banna, N., Loo, S. & Rampton, D.S. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an *in vitro* study, 197  
*lansoprazole*, 35, 291, 425, 553, 837, 881, 1149, 1811, 1933  
 Lanza, F. *see* Chen, C.L.  
*laser Doppler*, 1903  
 Lau, C.P. *see* Wong, W.-M.  
 Lau, S.F. *see* Yee, Y.K.  
 Lau, W.H. *see* You, J.H.S.  
 Lauritsen, K. *see* Hallerbäck, B.  
 Lavagna, A. *see* Della Monica, P.  
 Lavine, J.E. *see* Orenstein, S.R.  
 Le Borgne, J. *see* Gournay, J.  
 Le Néel, J.-C. *see* Gournay, J.  
 Leandro, G. *see* Rugge, M.  
 Lechago, J. *see* Rugge, M.  
*lectin*, 633  
 Ledermann, H. *see* Netzer, P.  
 Lee, C.K. *see* Yee, Y.K.  
 Lee, C.-L. *see* Liao, C.-C.  
 Lee, K.K.C. *see* You, J.H.S.  
 Lee, S.-C. *see* Liao, C.-C.  
 Lee, S.-D. *see* Luo, J.-C.  
 Lee, S.I. *see* Choi, I.J.  
 Lee, W.M. *see* Malik, A.H.  
 Lee, W.M. *see* Schiodt, F.V.  
 Lee, Y.M. *see* Lim, L.L.  
 Lee, Y.T. *see* Wu, J.C.Y.  
 Leeds HELP Study Group *see* Mason, J.  
 Lefkowitz, J. *see* Goldstein, J.L.  
 Lefkowitz, M. *see* Novick, J.  
 Lehmann, A. *see* Cange, L.  
 Lehn, N. *see* Feydt-Schmidt, A.  
 Lei, A. *see* Kuiken, S.D.  
 Lemann, M. *see* Sabate, J.M.  
 Lembcke, B. *see* Braden, B.  
 Lengsfeld, H. *see* Faas, H.  
 Leodolter, A. *see* Peitz, U.  
 Leong, R.W.L. & Sung, J.J.Y. Review article: *Helicobacter* species and hepatobiliary diseases, 1037  
 Leontiadis, G.I. *see* Levine, J.E.  
 Lerat, F. *see* Gournay, J.  
 Lerebours, E. *see* Abitbol, V.  
 Leroux-Roels, G. *see* Van Vlierberghe, H.  
 Leung, N.W.Y. *see* Cheng, A.S.L.  
 Leung, W.K. *see* Wu, J.C.Y.  
 Leung, W.K. & Sung, J.J.Y. Review article: intestinal metaplasia and gastric carcinogenesis, 1209  
 Levine, J.E., Leontiadis, G.I., Sharma, V.K. & Howden, C.W. Meta-analysis: the efficacy of intravenous H<sub>2</sub>-receptor antagonists in bleeding peptic ulcer, 1137  
*levosulpiride*, 613  
 Li, B.U.K. *see* Orenstein, S.R.  
 Li, K.F. *see* Yee, Y.K.  
 Liao, C.-C., Lee, C.-L., Chiang, T.-C., Lee, S.-C., Huang, S.-H., Tu, T.-C., Chen, T.-K. & Wu, C.-H. The <sup>13</sup>C-urea breath test to detect *Helicobacter pylori* infection: a validated simple methodology with 50 mg <sup>13</sup>C-urea, 787  
 Liew, C.T. *see* Cheng, A.S.L.  
 Ligozio, G. *see* Novick, J.  
 Lim, L.L., Wai, C.T., Lee, Y.M., Kong, H.L., Lim, R., Koay, E. & Lim, S.G. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients, 1939  
 Lim, R. *see* Lim, L.L.  
 Lim, S.G. *see* Lim, L.L.  
 Lin, H.-Y. *see* Luo, J.-C.  
 Lin, M.-D. *see* Sheu, B.-S.  
 Lin, Y.-S. *see* Sheu, B.-S.  
 Lind, T. *see* Malfertheiner, P.  
 Lionetti, P. *see* Barabino, A.  
 Lionello, M. *see* Manes, G.  
*lipid metabolism*, 1571  
*lipids*, 577  
*lipomatous polyposis*, 333  
*liquid enema*, 415  
*liver biopsy*, 1963  
*liver cirrhosis*, 1283, 1547  
*liver descriptors*, 707, 1977  
*liver disease*, 235, 1037  
*liver dysfunction*, 1939  
*liver failure*, 1539  
*liver transplantation*, 1833, 1963  
 Ljunghall, S. *see* Stockbrügger, R.W.  
 Lloyd, D.A.J. *see* Tinto, A.  
 Lo, C.-Y. *see* Sheu, B.-S.  
 Loeffler, V. *see* Holtmann, G.  
 Loftus Jr, E.V., Schoenfeld, P. & Sandborn, W.J. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review, 51  
 Logan, R.F.A. *see* Stack, W.A.  
 Lombardo, L. *see* Della Monica, P.  
*London*, 1709  
 Lonovics, J. *see* Malfertheiner, P.  
 Loo, S. *see* Langmead, L.  
 Lopez, S. *see* Moreno-Monteagudo, J.A.  
 Lorenzo, J.A. *see* Moreno-Monteagudo, J.A.  
*Los Angeles classification*, 2037  
 Losco, A. *see* Massironi, S.  
 Lourens, S.T. *see* Netzer, P.  
*lower oesophageal sphincter*, 473  
*loxiglumide*, 17  
 López-Sangomán, A. *see* Boixeda, D.  
 Lüscher, D. *see* Netzer, P.  
 Lu, C.-L. *see* Luo, J.-C.  
 Lu, H. *see* Wong, W.M.  
 Lu, R.-H. *see* Luo, J.-C.  
 Lui, H.F. *see* Tripathi, D.  
 Lumi, M. *see* Sambuelli, A.  
 Lundell, L. *see* Cange, L.



- Luo, J.-C., Chang, F.-Y., Lin, H.-Y., Lu, R.-H., Lu, C.-L., Chen, C.-Y. & Lee, S.-D. The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. 1241
- Lupascu, A. *see* Di Caro, S.
- Luybaerts, A. *see* Geboes, K.P.
- lymphocyte proliferation, 1903
- lymphoma, 1225
- Lymphoma Study Group, T.I.G. *see* Caletti, G.
- Maastricht, 167, 1443
- MacDonald, C. *see* Khan, Z.
- Mack, R.J. *see* Chen, C.L.
- Maconi, G. *see* Parente, F.
- macrolide, 315, 1481
- Madsen, L.G. & Bytzer, P. Review article: single subject trials as a research instrument in gastrointestinal pharmacology. 189
- Maes, B. *see* Geboes, K.P.
- Maev, I. *see* Isakov, V.
- magnesium citrate, 1327
- magnetic resonance imaging, 217
- Mahmud, N., O'Toole, D., O'Hare, N., Freyne, P.J., Weir, D.G. & Kelleher, D. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. 207
- Majeed, A. *see* Kang, J.-Y.
- Majeed, A. *see* Tinto, A.
- Malchow, H., Gertz, B. & the Clafoam Study Group. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. 415
- Malek, M. *see* Musch, E.
- Malet, P.F. *see* Malik, A.H.
- Malfatti, F. *see* Giannini, E.
- Mallfertheiner, P., Dent, J., Zeijlon, L., Sipponen, P., Veldhuyzen van Zanten, S.J.O., Burman, C.-F., Lind, T., Wrangstadh, M., Bayerdörfler, E. & Lonovics, J. Impact of *Helicobacter pylori* eradication on heartburn in patients with gastric or duodenal ulcer disease — results from a randomized trial programme. 1431
- Mallfertheiner, P., Mégraud, F., O'Morain, C., Hungin, A.P.S., Jones, R., Axon, A., Graham, D.Y., Tytgat, G. & The European *Helicobacter pylori* Study Group (EHPG). Current concepts in the management of *Helicobacter pylori* infection—The Maastricht 2-2000 Consensus Report. 167
- Mallfertheiner, P. *see* Ebert, M.P.A.
- Mallfertheiner, P. *see* Peitz, U.
- Mallfertheiner, P. *see* Pilotto, A.
- malignancy, 1225, 1939
- Malik, A.H., Kumar, K.S., Malet, P.F., Ostapowicz, G., Adams, G., Wood, M., Yarbrough, K., Jones, A. & Lee, W.M. A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon. 381
- malondialdehyde, 985
- MALT lymphoma, 1715
- management strategies, 261, 1491
- Mandelkern, M. *see* Mayer, E.A.
- Manes, G., Balzano, A., Marone, P., Lioniello, M. & Mosca, S. Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system: a prospective observational study based on the Maastricht guidelines. 105
- Manfredi, R., Calza, L. & Chiodo, F. Gabexate mesilate and/or octreotide in human immunodeficiency virus-associated pancreatic abnormalities. 1791
- Manfrin, V. *see* Fabris, P.
- Manguso, F. *see* Rizzello, F.
- Mansfield, J.C., Gaffar, M.H., Cann, P.A., McKenna, D., Thornton, P.C. & Holdsworth, C.D. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. 69
- Mansfield, J.C. *see* Green, J.R.B.
- Mansi, C. *see* Bilardi, C.
- Mansi, C. *see* Zentilin, P.
- Marcheggiano, A. *see* Paoluzi, O.A.
- Marchioretto, M.A.M. *see* Ortiz, R.A.M.
- Marinaki, A. *see* Ansari, A.
- Marino, G., Rustgi, V.K., Salzberg, G., Johnson, L.B., Kuo, P.C., Plotkin, J.S. & Flockhart, D.A. Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. 235
- Markov chain, 41
- Marone, P. *see* Manes, G.
- Marteau, P., Cuillerier, E., Meance, S., Gerhardt, M.F., Myara, A., Bouvier, M., Bouley, C., Tondou, F., Bommelaer, G. & Grimaud, J.C. *Bifidobacterium animalis* strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. 587
- Martin, T. *see* Gournay, J.
- Martín-De-Argila, C. *see* Boixeda, D.
- Mary, J.Y. *see* Abitbol, V.
- Mas, P. *see* Calvet, X.
- Masala, G. *see* Palli, D.
- Masclée, A.A.A. *see* Kamerling, I.M.C.
- Masliyah, C. *see* Gournay, J.
- Masoero, G. *see* Della Monica, P.
- Mason, J., Axon, A.T.R., Forman, D., Duffett, S., Drummond, M., Crocombe, W., Feltbower, R., Mason, S., Brown, J. & Moayyedi, P. (on behalf of the Leeds HELP Study Group). The cost-effectiveness of population *Helicobacter pylori* screening and treatment: a Markov model using economic data from a randomized controlled trial. 559
- Mason, S. *see* Mason, J.
- Massironi, S., Losco, A., Basilisco, G., Wicks, A.C.B., Thomas, C., Curran, R. & Mayberry, J.F. Letters to the Editors. 1831
- maternal infection, 1677
- Maxwell, J.D. *see* Tinto, A.
- Mayberry, J.F. *see* Massironi, S.
- Mayer, E.A., Berman, S., Derbyshire, S.W.G., Suyenobu, B., Chang, L., Fitzgerald, L., Mandelkern, M., Hamm, L., Vogt, B. & Naliboff, B.D. The effect of the 5-HT<sub>3</sub> receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. 1357

- Mayr, P. *see* Holtmann, G.  
 McCallum, R. *see* Pehlivanov, N.  
 McGovern, D. *see* Fraser, A.G.  
 McGuire, A.J. *see* Robinson, M.  
 McGuire, J.A. *see* Orenstein, S.R.  
 McIsaac, R.L. *see* Gardner, J.D.  
 McKenna, D. *see* Mansfield, J.C.  
 McKinzie, S. *see* Kuo, B.  
 McPhail, G. *see* Zulu, I.  
 Maday, E. *see* De Block, C.E.M.  
 MDR, 1021  
 Meance, S. *see* Marteau, P.  
 Mee, A.S. *see* Mitchell, S.A.  
 Meenan, J. *see* Ansari, A.  
 Mele, M.R. *see* Bilardi, C.  
 Mele, M.R. *see* Zentilin, P.  
 Menconi, M.J. *see* Farrell, R.J.  
 Mendall, M.A. *see* Poullis, A.  
 Menegatti, M. *see* Palli, D.  
 Mentis, A. *see* Georgopoulos, S.D.  
 Menzel, J. *see* Ullrich, H.  
*mercaptopurine*, 181  
 Merla, A. *see* Perri, F.  
*mesalazine*, 647, 1889, 2053  
*mesenteric disorder*, 2115  
*mesenteric panniculitis*, 2115  
*meta-analysis*, 1137, 1509, 1611, 1623  
*methotrexate*, 647, 693, 1751  
*metronidazole*, 27, 569, 793, 909, 1047, 1457, 2067  
 Metz, M. *see* Holtmann, G.  
 Meuwissen, S.G.M. *see* Sloots, C.E.J.  
 Mégraud, F. *see* Mallertheiner, P.  
*microsomal hepatic function*, 1977  
 Middleton, S.J., Naylor, S., Woolner, J. & Hunter, J.O. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis, 1131  
 Midhagen, G. *see* Hallert, C.  
 Miele, L. *see* Armuzzi, A.  
 Miglioli, M. *see* Bortolotti, M.  
 Miglioli, M. *see* Palli, D.  
 Mihara, M. *see* Ito, M.  
 Milicua, J.M. *see* Boixeda, D.  
 Milione, M. *see* Lahner, E.  
 Miller, N. *see* Warrington, S.  
 Mills, P.R. *see* Stockbrügger, R.W.  
 Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I.C., Nicholls, R.J., Gionchetti, P., Campieri, M. & Kamm, M.A. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis, 909  
 Miner Jr, P.B. *see* Collings, K.L.  
 Miner Jr, P.B. *see* Gardner, J.D.  
 Miner, P. *see* Novick, J.  
 Miner, P.B. *see* Robinson, M.  
 Miska, D. *see* Kovacs, T.O.G.  
 Mitchell, S.A., Mee, A.S., Smith, G.D., Palmer, K.R. & Chapman, R.W. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial, 1187  
*mitochondrial liver function*, 1977  
 Mitry, E. *see* Faivre-Finn, C.  
 Miwa, H. *see* Hojo, M.  
*mixed infection*, 2073  
 Miyake, K. *see* Futagami, S.  
 Miyazawa, M. *see* Suzuki, M.  
 Moayyedi, P. *see* Mason, J.  
 Modigliani, R. *see* Sabate, J.M.  
 Mohnen, J. *see* Hirschowitz, B.I.  
 Moniz, C. *see* Lamb, E.J.  
 Montgomery, S.M. *see* Wakefield, A.J.  
 Montigny, P. *see* Gournay, J.  
 Mordenti, J. *see* Tremaine, W.J.  
 Morelli, A. *see* Distrutti, E.  
 Morelli, P. *see* Bazzoli, F.  
 Moreno, V. *see* Elizalde, J.I.  
 Moreno-Monteagudo, J.A., Castro, A., De Pedro, A., Lorenzo, J.A., Fernández-Bermejo, M., Lopez, S., García-Buey, L., Borque, M.J., Pedreira, J.D. & Moreno-Otero, R. Interferon- $\alpha$  plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers, 243  
 Moreno-Otero, R. *see* Moreno-Monteagudo, J.A.  
 Mori, H. *see* Saitoh, T.  
 Morillas, J.D. *see* Elizalde, J.I.  
 Morocutti, A. *see* Warrington, S.  
 Morsiani, E. *see* Pazzi, P.  
*mortality*, 2037  
 Morton, D. *see* Fraser, A.G.  
*mosapride*, 959  
 Mosca, S. *see* Manes, G.  
*motilide*, 1481  
*motilin*, 129  
*motility*, 603, 743  
*motility and nerve-gut interactions*, 1171, 1571, 1781, 1955  
*moxifloxacin*, 527  
*mucosal injury*, 847  
 Muhtarov, M. *see* Tankova, L.  
 Mullan, B.P. *see* Cremonini, F.  
 Muller, A.F. *see* Lamb, E.J.  
 Muraca, M. *see* Pazzi, P.  
 Murakami, K., Sato, R., Okimoto, T., Nasu, M., Fujioka, T., Kodama, M., Kagawa, J., Sato, S., Abe, H. & Arita, T. Eradication rates of clarithromycin-resistant *Helicobacter pylori* using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin, 1933  
 Murata, I. *see* Yoshikawa, I.  
 Murch, S.H. *see* Wakefield, A.J.  
 Murray, H. *see* Eslick, G.D.  
 Murray, J.A. *see* Nzeako, U.C.  
 Murthy, A. *see* Robinson, M.  
 Musch, E., Andus, T. & Malek, M. Induction and maintenance of clinical remission by interferon- $\beta$  in patients with steroid-

- refractory active ulcerative colitis—an open long-term pilot trial, 1233
- Musulien, E. *see* Calvet, X.
- Myara, A. *see* Marteau, P.
- Nagahashi, S. *see* Suzuki, M.
- Nakamura, H. *see* Yoshikawa, I.
- Naliboff, B.D. *see* Mayer, E.A.
- naloxone*, 1649
- Nasu, M. *see* Murakami, K.
- natalizumab*, 699
- Nault, B. *see* Tougas, G.
- nausea*, 225
- Naylor, S. *see* Middleton, S.J.
- Negreira, S. *see* Sambuelli, A.
- Netzer, P., Gaia, C., Lourens, S.T., Reber, P., Wildi, S., Noelpp, U., Ritter, E.P., Ledermann, H., Lüscher, D., Varga, L., Kinser, J.A., Büchler, M.W. & Scheurer, U. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? 119
- Netzer, P., Schmitt, B. & Inauen, W. Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease, 1481
- Netzer, R., DeGiorgio, M.C., Bateson, H.K., Parsons, P. *see* De Ponti, F.
- neurodevelopment*, 663
- neuroleptics*, 1539
- neutrophil*, 159
- Nevens, F. *see* Van De Casteele, M.
- New York, 1709
- Newton, J.M. *see* Tuleu, C.
- Ng, F.H., Wong, W.M., Wong, B.C.Y., Kng, C., Wong, S.Y., Lai, K.C., Cheng, C.S., Yuen, W.C., Lam, S.K. & Lai, C.L. Sequential intravenous/oral antibiotic vs. continuous intravenous antibiotic in the treatment of pyogenic liver abscess, 1083
- Nicholls, R.J. *see* Mimura, T.
- Nicholls, T.J. *see* Emmanuel, A.V.
- Nicolini, G. *see* Bazzoli, F.
- Ni'Muircheartaigh, R. *see* Sengupta, S.
- Nista, E.C. *see* Armuzzi, A.
- Nista, E.C. *see* Cremonini, F.
- Nista, E.C. *see* Di Caro, S.
- nitrates*, 1945
- nitroimidazole*, 315
- nizatidine*, 297, 2043
- nociceptive fibres*, 1075
- nocturnal acid breakthrough*, 1309
- Noelpp, U. *see* Netzer, P.
- N-of-1 trials*, 189
- non-cardiac chest pain*, 465, 1217
- non-responders*, 1611
- non-response*, 1743
- non-steroidal anti-inflammatory drugs*, 497, 1241, 1945
- non-surgical*, 1
- non-transferrin-bound iron*, 1555
- non-ulcer dyspepsia*, 1689
- normal values*, 1781
- North America*, 51
- Northfield, T.C. *see* Poullis, A.
- Noel, J.F. *see* Gournay, J.
- Novick, J., Miner, P., Krause, R., Glebas, K., Bliesath, H., Ligozio, G., Rüegg, P. & Lefkowitz, M. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation, 1877
- NSAID*, 847
- nuclear factor  $\kappa$ B (NF $\kappa$ B)*, 1579
- nucleoside analogue*, 1939
- nutrition*, 799
- Nygard, G. *see* Stockbrügger, R.W.
- Nzeako, U.C. & Murray, J.A. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy, 1309
- observational study*, 1663
- obstructive jaundice*, 727
- O'Connor, H.J. *Helicobacter pylori* and dyspepsia: physicians' attitudes, clinical practice, and prescribing habits, 487
- O'Connor, M.K. *see* Kuo, B.
- octreotide*, 769, 1563, 1791
- O'Donnell, L.J.D. *see* Sengupta, S.
- oesophageal*, 799
- oesophageal disorder*, 1209, 1955
- oesophageal manometry*, 893
- oesophageal motility*, 1481
- oesophageal pH monitoring*, 545
- oesophageal pH*, 1655
- oesophageal stricture*, 1795
- oesophageal ulcer*, 1795
- oesophagitis*, 2037
- oesophagus*, 2029
- Ofman, J.J., Dorn, G.H., Fennerty, M.B. & Fass, R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease, 261
- Ogawa, K. *see* Saitoh, T.
- O'Hare, N. *see* Mahmud, N.
- Ohashi, K. *see* Shirai, N.
- Ohkawa, S. *see* Saitoh, T.
- Ohkura, R. *see* Hojo, M.
- Ohkusa, T. *see* Hojo, M.
- Ojeburu, J.V. *see* Bashir, S.
- Ojetti, V. *see* Di Caro, S.
- Okimoto, T. *see* Murakami, K.
- Olden, K. *see* El-Serag, H.B.
- Oldenburg, B. *see* van Balkom, B.P.J.
- O'Leary, J.J. *see* Wakefield, A.J.
- Olyae, M. *see* Pehlivanov, N.
- omeprazole*, 35, 137, 145, 479, 553, 569, 1149, 1163, 1431, 1811
- O'Morain, C. *see* Malfertheiner, P.
- oncology*, 1059
- ondansetron*, 119
- Ono, M. *see* Adachi, K.
- opioid analgesics*, 1539

- Opolon, P. *see* Goulenok, C.  
 oral contraceptives, 1539  
 Orchard, T.R. *see* Fraser, A.G.  
 Orenstein, S.R., Blumer, J.L., Faessel, H.M., McGuire, J.A., Fung, K., Li, B.U.K., Lavine, J.E., Grunow, J.E., Treem, W.R. & Ciociola, A.A. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux, 899  
 Orr, W.C. *see* Chen, C.L.  
 Ortiz, R.A.M., Calafatti, S.A., Corazzi, A., Souza, J.M., Deguer, M., De Souza, C.A.F., Marchioretto, M.A.M., Bernasconi, G., Ferraz, J.G.P. & Pedrazzoli Jr, J. Amoxicillin and ampicillin are not transferred to gastric juice irrespective of *Helicobacter pylori* status or acid blockade by omeprazole, 1163  
 Ostapowicz, G. *see* Malik, A.H.  
 osteoporosis, 919, 1519, 1895  
 O'Toole, D. *see* Mahmud, N.  
 Otsuka, H. *see* Saitoh, T.  
 Otsuki, M. *see* Yoshikawa, I.  
 Ott, P. *see* Schiodt, F.V.  
 Otten, M.H. *see* Tougas, G.  
 outcomes research, 1003  
 oxidative stress, 1997  
 pain, 225, 1075  
 Paineau, J. *see* Gournay, J.  
 Pajares, J.M. *see* Gisbert, J.P.  
 Palli, D., Menegatti, M., Masala, G., Ricci, C., Saieva, C., Holton, J., Gatta, L., Miglioli, M. & Vaira, D. *Helicobacter pylori* infection, anti-cagA antibodies and peptic ulcer: a case-control study in Italy, 1015  
 palliative chemotherapy, 353  
 Palmer, K.R. *see* Mitchell, S.A.  
 Palmer, T. *see* Gordon, F.H.  
 pancreatic abnormalities, 1791  
 pancreatic disorders, 1831, 2097  
 Pandolfo, N. *see* Zentilin, P.  
 pantoprazole, 425, 553, 1457, 2043  
 Paoluzi, O.A., Pica, R., Marcheggiano, A., Crispino, P., Iacopini, F., Iannoni, C., Rivera, M. & Paoluzi, P. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission, 1751  
 Paoluzi, P. *see* Paoluzi, O.A.  
 paracetamol, 1539  
 Parente, F., Bargiggia, S. & Bianchi Porro, G. Prospective audit of gastroscopy under the 'three-day rule': a regional initiative in Italy to reduce waiting time for suspected malignancy, 1011  
 Parente, F., Sainaghi, M., Sangalietti, O., Imbesi, V., Maconi, G., Anderloni, A. & Bianchi Porro, G. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the  $^{13}\text{C}$ -urea breath test, 553  
 Parente, F. *see* Caletti, G.  
 parietal cell antibodies, 281  
 Park, M.J. *see* Kim, J.S.  
 Parker, R.A. *see* Speechler, S.J.  
 paroxetine, 1091  
 Parsonnet, J. *see* Passaro, D.J.  
 Passaro, D.J., Hurwitz, A., Triadafilopoulos, G. & Parsonnet, J. A modification of the quininium resin test for assessing gastric acidity, 875  
 pathogenesis, 1037  
 pathogenicity island, 1015  
 pathophysiology, 1407  
 patients, 1877  
 patients compliance, 527, 1889, 2053  
 Pazzi, P., Morsiani, E., Vilei, M.T., Granato, A., Rozga, J., Demetriou, A.A. & Muraca, M. Serum bile acids in patients with liver failure supported with a bioartificial liver, 1547  
 PCA, 799  
 Peña, B.M. *see* Goldstein, J.L.  
 Pecher, E. *see* Tougas, G.  
 Pedersen, N.L. *see* Svedberg, P.  
 pediatric, 899  
 Pedrazzoli Jr, J. *see* Ortiz, R.A.M.  
 Pedreira, J.D. *see* Moreno-Monteagudo, J.A.  
 Pehlivanov, N., Sarosiek, I., Whitman, R., Olyace, M. & McCallum, R. Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study, 743  
 Peitz, U., Sulliga, M., Wolle, K., Leodolter, A., Von Arnim, U., Kahl, S., Stolte, M., Börsch, G., Labenz, J. & Malfertheiner, P. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure *Helicobacter pylori* infection: impact of two second-line therapies in a randomized study, 315  
 Pelckmans, P.A. *see* De Block, C.E.M.  
 Pensi, M.O. *see* Distrutti, E.  
 pepsin, 303  
 pepsinogen A/C ratio, 1805  
 pepsinogen I, 1723  
 peptic disease, 1469  
 peptic ulcer bleeding, 137  
 peptic ulcer disease, 1241  
 peptic ulcer, 497, 1015, 1067, 1163, 1203, 1945  
 percutaneous ethanol injection, 1529  
 Pera, A. *see* Della Monica, P.  
 Perdomo, C. *see* Gardner, J.D.  
 Peredo, A. *see* Sambuelli, A.  
 Perri, F., Ricciardi, R., Merla, A., Piepoli, A., Gasperi, V., Quitadamo, M. & Andriulli, A. Appropriateness of urea breath test: a prospective observational study based on Maastricht 2000 guidelines, 1443  
 Persson, T. *see* Stockbrügger, R.W.  
 Petty, K.J. *see* Van Hecken, A.  
 Peyre, S. *see* Caletti, G.  
 PGA, 799  
 PGC, 799  
 P-glycoprotein, 1021  
 pH, 303  
 pharmaceutical industry, 1859  
 pharmacodynamics, 899

- pharmacoeconomy, 1269  
 pharmacokinetics, 235, 899, 1163  
 phasic motility, 985  
 pH-metry, 893  
 pH-monitoring, 869  
 phytohaemagglutinin, 633  
 Pica, R. *see* Paoluzi, O.A.  
 Picard, C., Ksas, B., Griffiths, N.M. & Fioramonti, J. Effect of granisetron on radiation-induced alterations of colonic motility and fluid absorption in rats, 623  
 Piccinino, F. *see* Gaeta, G.B.  
 Piepoli, A. *see* Perri, F.  
 Pileri, S. *see* Caletti, G.  
 Pilmer, B.L. *see* Huang, J.-Q.  
 Pilotto, A. *see* Fabris, P.  
 Pilotto, A. & Malfertheiner, P. Review article: an approach to *Helicobacter pylori* infection in the elderly, 683  
 Piqué, J.M. *see* Elizalde, J.I.  
 placebo-controlled study, 959  
 platelets, 577  
 Playford, R.J. *see* Khan, Z.  
 Plotkin, J.S. *see* Marino, G.  
 Pochapin, M.B. *see* Rex, D.K.  
 Poen, A.C. *see* Sloots, C.E.J.  
 Poggioli, G. *see* Mimura, T.  
 poisoning, 1539  
 Polegato, S. *see* Giannini, E.  
 polyethylene glycol, 1327  
 polyps, 1197  
 Poon, S.K., Chang, C.S., Su, J., Lai, C.H., Yang, C.C., Chen, G.H. & Wang, W.-C. Primary resistance to antibiotics and its clinical impact on the efficacy of *Helicobacter pylori* lansoprazole-based triple therapies, 291  
 population screening, 559  
 population survey, 2081  
 Poremba, C. *see* Ullerich, H.  
 portal hypertension, 373  
 Porter, J. *see* Högenauer, C.  
 Postma, M.J. *see* Klok, R.M.  
 post-sphincterotomy bleeding, 929  
 pouchitis, 27, 909  
 Poullis, A., Foster, R., Northfield, T.C. & Mendall, M.A. Review article: faecal markers in the assessment of activity in inflammatory bowel disease, 675  
 Pounder, R.E. *see* Gordon, F.H.  
 Poynard, T. *see* Goulenok, C.  
 Pozzato, P. *see* Bazzoli, F.  
 Prada, A. *see* Rizzello, F.  
 Praet, M. *see* Van Vlierberghe, H.  
 prebiotic, 1591  
 Precone, D.F. *see* Gaeta, G.B.  
 Price, A.B. *see* Rugge, M.  
 Prinz, C. *see* Volland, P.  
 Probert, C.S.J. *see* Shaw, I.S.  
 probiotics, 587, 1461  
 proctocolectomy, 27  
 prokinetic, 1347  
 prokinetic drugs, 749  
 prolonged manometry study, 985  
 propranolol, 373  
 Proskin, H.M. *see* Collings, K.L.  
 prospective follow-up study, 2037  
 proton pump inhibitor, 159, 473, 819, 1047, 1301, 1149  
 prucalopride, 603, 759  
 Pruitt, R.E. *see* Tougas, G.  
 Puig, J. *see* Calvet, X.  
 Puleston, J.M. *see* Wakefield, A.J.  
 Puolakkainen, P. *see* Kokkola, A.  
 pyogenic liver abscess, 1083  
  
 quadruple therapy, 569, 1261, 1457  
 quality of life, 909, 1101, 1143, 1347, 1603  
 Que, T.L. *see* Yee, Y.K.  
 questionnaire, 1101  
 quinine, 875  
 quininium resin, 875  
 Quitadamo, M. *see* Perri, F.  
 Qureshi, W. *see* Verghese, V.J.  
  
 rabeprazole, 445, 455, 479, 1149, 1301, 1811, 1933  
 Rades, T. *see* Faas, H.  
 Rakatansky, H. Review article: gastroenterology and the pharmaceutical industry, 1859  
 Rampton, D.S. *see* Langmead, L.  
 randomized controlled trial, 479, 559  
 randomized trial, 569  
 ranitidine, 899, 1317  
 ranitidine bismuth citrate, 2067  
 Rank, M.R. *see* Cremonini, F.  
 rapid urine test, 813  
 Raptis, S.A. *see* Georgopoulos, S.D.  
 Rassiat, E. *see* Faivre-Finn, C.  
 rat, 623  
 Rautelin, H. *see* Kokkola, A.  
 Rea, P. *see* Franzese, A.  
 reactive oxygen metabolites, 197, 1997  
 Reber, P. *see* Neizer, P.  
 reflux, 35, 881  
 reflux disease, 41  
 reflux oesophagitis, 545, 887, 1431  
 Rüegg, P. *see* Novick, J.  
 relapsers, 243  
 renal and urinary tract problems, 975  
 renal function, 207  
 repair, 1917  
 reproducibility, 1781  
 rescue, 1047  
 resistance, 315  
 resistance to metronidazole, 1277  
 responder, 1805  
 restorative, 27  
 retreatment, 1047  
 Rew, J.S. *see* Choi, I.J.



- Rex, D.K., Chasen, R. & Pochapin, M.B. Safety and efficacy of two reduced dosing regimens of sodium phosphate tablets for preparation prior to colonoscopy, 937
- Rhee, J.C. *see* Choi, I.J.
- rheumatoid arthritis, 1291
- Rhodes, J. *see* Hawkes, N.D.
- Rhodes, P. *see* Hawkes, N.D.
- ribavirin, 234, 381, 1611, 1623, 1633, 2107
- Ricci, C. *see* Palli, D.
- Ricciardi, R. *see* Perri, F.
- Ricciardiello, L. *see* Bazzoli, F.
- Richou, C. *see* Gournay, J.
- ridogrel, 87
- Riff, D. *see* Chen, C.L.
- risk factors, 1519, 1623
- Ritter, E.P. *see* Netzer, P.
- Rivera, M. *see* Paoluzi, O.A.
- Rizzello, F., Gionchetti, P., D'Arienzo, A., Manguso, F., Di Matteo, G., Annesse, V., Valpiani, D., Casetti, T., Adamo, S., Prada, A., Castiglione, G.N., Varoli, G. & Campieri, M. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study, 1109
- Rizzello, F. *see* Mimura, T.
- Robinson, E.M. *see* Fraser, A.G.
- Robinson, M., Fitzgerald, S., Hegedus, R., Murthy, A. & Jokubaitis, L. (on behalf of the FAST trial investigators). Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis, 445
- Robinson, M., Rodriguez-Stanley, S., Miner, P.B., McGuire, A.J., Fung, K. & Ciociola, A.A. Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn, 435
- Robinson, M. *see* Collings, K.L.
- Robinson, M. *see* Gardner, J.D.
- Roda, E. *see* Bazzoli, F.
- Rodriguez-Stanley, S. *see* Collings, K.L.
- Rodriguez-Stanley, S. *see* Gardner, J.D.
- Rodriguez-Stanley, S. *see* Robinson, M.
- Rojavin, M.A. *see* Tougas, G.
- Romagnoli, P. *see* Giannini, E.
- Ros, E. *see* Elizalde, J.I.
- Rosinach, M. *see* Domènech, E.
- Rothenbacher, D., Bode, G. & Brenner, H. Dynamics of *Helicobacter pylori* infection in early childhood in a high-risk group living in Germany: loss of infection higher than acquisition, 1663
- Roux, C. *see* Abitbol, V.
- Rowley-Jones, D. *see* Gordon, F.H.
- Roy, A.J. *see* Emmanuel, A.V.
- Rozga, J. *see* Pazzi, P.
- Rüssmann, H. *see* Feydt-Schmidt, A.
- Rubin, G., Hungin, A.P.S., Chinn, D., Dwarakanath, A.D., Green, L. & Bates, J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey, 1889
- Rugge, M., Correa, P., Dixon, M.F., Fiocca, R., Hattori, T., Lechago, J., Leandro, G., Price, A.B., Sipponen, P., Solcia, E., Watanabe, H. & Genta, R.M. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading, 1249
- Russel, M.G.V.M. *see* van Balkom, B.P.J.
- Rustgi, V.K. *see* Marino, G.
- Rutgeerts, P. *see* Geboes, K.P.
- Ruth, M. *see* Cange, L.
- Rydholm, H. *see* Cange, L.
- Rydholm, H. *see* Van Herwaarden, M.A.
- Rydén-Bergsten, T. *see* Vakil, N.
- Sabate, J.M., Villarejo, J., Lemann, M., Bonnet, J., Allez, M. & Modigliani, R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease, 1117
- Saccharomyces boulardii*, 1461
- Sachs, G. *see* Voland, P.
- Safdi, M. *see* Sands, B.E.
- safety, 1623, 1701
- Saieva, C. *see* Palli, D.
- Sainaghi, M. *see* Parente, F.
- Saitoh, T., Fukushima, Y., Otsuka, H., Hirakawa, J., Mori, H., Asano, T., Ishikawa, T., Katsube, T., Ogawa, K. & Ohkawa, S. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers, 1811
- Sakamoto, C. *see* Futagami, S.
- salivary secretion, 297
- salvage, 1047
- Salzberg, B. *see* Sands, B.E.
- Salzberg, G. *see* Marino, G.
- Sambuelli, A., Boerr, I., Negreira, S., Gil, A., Camartino, G., Huernos, S., Kogan, Z., Cabanne, A., Graziano, A., Peredo, A., Doldán, I., Gonzalez, O., Sugai, E., Lumi, M. & Bai, J.C. Budesonide enema in pouchitis—a double-blind, double-dummy, controlled trial, 27
- Sampliner, R.E. *see* Sonnenberg, A.
- Samsom, M. *see* Clemens, C.H.M.
- Samsom, M. *see* De Schryver, A.M.P.
- Samsom, M. *see* Van Herwaarden, M.A.
- San Miguel, R., Guillén, F., Cabasés, J.M. & Buti, M. Meta-analysis: combination therapy with interferon- $\alpha$  2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon, 1611
- Sandborn, W.J. *see* Kane, S.V.
- Sandborn, W.J. *see* Loftus Jr, E.V.
- Sanderson, J. *see* Ansari, A.
- Sands, B.E., Winston, B.D., Salzberg, B., Safdi, M., Barish, C., Wruble, L., Wilkins, R., Shapiro, M., Schwertschlag, U.S. & the rIL-11 Crohn's Study Group. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease, 399
- Sanfeliu, I. *see* Calvet, X.
- Sangaletti, O. *see* Parente, F.
- Santa Ana, C. *see* Högenauer, C.
- Sarosiek, I. *see* Pehlivanov, N.



- Sasaki, M., FitzGerald, A.J., Grant, G., Ghatei, M.A., Wright, N.A. & Goodlad, R.A. Lectins can reverse the distal intestinal atrophy associated with elemental diets in mice, 633
- Sato, N. *see* Hojo, M.
- Sato, R. *see* Murakami, K.
- Sato, S. *see* Murakami, K.
- Savarino, V. *see* Bilardi, C.
- Savarino, V. *see* Frazzoni, M.
- Savarino, V. *see* Zentilin, P.
- Schaub, M. *see* Braden, B.
- Scheiman, J.M. *see* Ladabaum, U.
- Scheurer, U. *see* Netzer, P.
- Scheurlen, M. *see* Kraus, M.R.
- Schäfer, A. *see* Kraus, M.R.
- Schiødt, F.V., Lee, W.M., Bondesen, S., Ott, P. & Christensen, E. Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose, 707
- Schmidt, L.E. & Dalhoff, K. The effect of regular medication on the outcome of paracetamol poisoning, 1539
- Schmitt, B. *see* Netzer, P.
- Schnée, M. *see* Gournay, J.
- Schnell, T.G. *see* Avidan, B.
- Schoemaker, H.C. *see* Kamerling, I.M.C.
- Schoenfeld, P. *see* Kane, S.V.
- Schoenfeld, P. *see* Loftus Jr, E.V.
- Schoon, E.J. *see* Stockbrügger, R.W.
- Schoon, E.J. *see* van Balkom, B.P.J.
- Schreiber, S. *see* Mimura, T.
- Schwartz, S. *see* Chen, C.L.
- Schwertschlag, U.S. *see* Sands, B.E.
- Schwizer, W. *see* Faas, H.
- Scott, B.B. *see* Cunliffe, R.N.
- screening for colorectal cancer, 1197
- second-line, 793, 1047
- second-line therapy, 569
- second-line treatment, 315
- Seed, P. *see* Ansari, A.
- selective serotonin<sub>4</sub>receptor agonist, 759
- Sengupta, S., Cooney, R., Baj, M., Ni'Muircheartaigh, R. & O'Donnell, L.J.D. Prokinetic effect of indoramin, an  $\alpha$ -adrenergic antagonist, on human gall-bladder, 1801
- sensitivity, 735
- sequential therapy, 1083
- Seriolo, B. *see* Zentilin, P.
- serological tests, 521
- serology, 507, 533, 1015
- serotonin, 1357, 1367
- serotonin receptors, 1563
- Serrano, P., Lanas, A., Arroyo, M.T. & Ferreira, I.J. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases, 1945
- Serrano, P. *see* Lanas, A.
- serum gastrin, 1301
- Servaes, R. *see* Van De Casteele, M.
- Sewell, K.L. *see* Yacyshyn, B.R.
- Sham, F.N.F. *see* Xia, H.H.-X.
- Shapiro, M. *see* Sands, B.E.
- Sharma, V.K. *see* Levine, J.E.
- Shaw, I.S., Jobson, B.A., Silverman, D., Ford, J., Hearing, S.D., Ball, D., Johnson, E., Day, A. & Probert, C.S.J. Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds, 2053
- Sheu, B.-S., Chi, C.-H., Huang, C.-C., Kao, A.-W., Wang, Y.-L. & Yang, H.-B. Impact of intravenous omeprazole on *Helicobacter pylori* eradication by triple therapy in patients with peptic ulcer bleeding, 137
- Sheu, B.-S., Wu, J.-J., Lo, C.-Y., Wu, H.-W., Chen, J.-H., Lin, Y.-S. & Lin, M.-D. Impact of supplement with *Lactobacillus*- and *Bifidobacterium*-containing yogurt on triple therapy for *Helicobacter pylori* eradication, 1669
- Shirai, N., Furuta, T., Xiao, F., Kajimura, M., Hanai, H., Ohashi, K. & Ishizaki, T. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups, 837
- Shirai, N. *see* Furuta, T.
- Shobowale-Bakre, E.-M. *see* Ansari, A.
- short- and long-segment, 893
- Sianongo, S. *see* Zulu, I.
- side effects, 647, 1125, 1503, 1831
- Sik Chung, I. *see* Choi, I.J.
- Silverman, D. *see* Shaw, I.S.
- simethicone, 1641
- Simmons, J. *see* Hirschowitz, B.I.
- Simpson, D.E. *see* Lamb, E.J.
- Singh, S. *see* Hulin, S.J.
- single-subject trials, 189
- Sáinz, R. *see* Lanas, A.
- Sipponen, P. *see* Kokkola, A.
- Sipponen, P. *see* Mallertheiner, P.
- Sipponen, P. *see* Rugge, M.
- Sloan, S. *see* Gardner, J.D.
- Sloots, C.E.J., Poen, A.C., Kerstens, R., Stevens, M., De Pauw, M., Van Oene, J.C., Meuwissen, S.G.M. & Felt-Bersma, R.J.F. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation, 759
- small intestine, 769
- Smith, D.J. *see* Lamb, E.J.
- Smith, G.D. *see* Mitchell, S.A.
- smoking, 497
- Smout, A.J.P.M. *see* Clemens, C.H.M.
- Smout, A.J.P.M. *see* De Schryver, A.M.P.
- Smout, A.J.P.M. *see* Van Herwaarden, M.A.
- Snape Jr, W.J. *see* Tougas, G.
- sodium phosphate, 937
- Soergel, K.H. *see* Huilgol, V.
- Sofliati, G. *see* Fabris, P.
- Solcia, E. *see* Rugge, M.
- Soloway, R.D. *see* Chen, C.L.
- Song, I.S. *see* Kim, J.S.
- Soni, A. *see* Sonnenberg, A.
- Sonnenberg, A., Soni, A. & Sampliner, R.E. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma, 41
- Sonnenberg, A. *see* Avidan, B.

- Sonnenberg, A. *see* Baron, J.H.  
 Sonnenberg, A. & Gavin, M.W. General principles to enhance practice patterns in gastrointestinal endoscopy, 1003  
 Sontag, S.J. *see* Avidan, B.  
 Soulé, J.C. *see* Abitbol, V.  
 Souza, J.M. *see* Ortiz, R.A.M.  
 Spadaro, A. *see* Gaeta, G.B.  
 Spechler, S.J., Jain, S.K., Tendler, D.A. & Parker, R.A. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease, 1795  
*species*, 1037  
*specificity*, 735  
 Spiliadi, C. *see* Georgopoulos, S.D.  
 Spurrett, B. *see* Eslick, G.D.  
 Sridhar, S. *see* Huang, J.-Q.  
 SSRI, 1091  
 Stack, W.A., Atherton, J.C., Hawkey, G.M., Logan, R.F.A. & Hawkey, C.J. Interactions between *Helicobacter pylori* and other risk factors for peptic ulcer bleeding, 497  
*stage at diagnosis*, 353  
 Stagg, A.J. *see* Hart, A.L.  
 Stanley, A.J. *see* Tripathi, D.  
 Stanzione, M. *see* Gaeta, G.B.  
 Steingoetter, A. *see* Faas, H.  
*stenosis*, 1203  
*steroid-refractoriness*, 2061  
 Stevens, M. *see* Sloots, C.E.J.  
 Stockbrügger, R.W., Schoon, E.J., Bollani, S., Mills, P.R., Israeli, E., Landgraf, L., Felsenberg, D., Ljunghall, S., Nygard, G., Persson, T., Grafner, H., Bianchi Porro, G. & Ferguson, A. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease, 1519  
 Stockbrügger, R.W. *see* van Balkom, B.P.J.  
*stol*, 1723  
*stol test*, 1663  
 Stolte, M. *see* Peitz, U.  
*stomach*, 225, 1075  
*stool antigen assay*, 1733  
 Stornaiuolo, G. *see* Gaeta, G.B.  
 Strenkoski-Nix, L.C. *see* Tremaine, W.J.  
*stress*, 2017  
 Störk, D. *see* Feydt-Schmidt, A.  
 Ström, M. *see* Hallert, C.  
 Su, J. *see* Poon, S.K.  
 Sugai, E. *see* Sambuelli, A.  
*sulfasalazine*, 61, 69, 647  
 Sulliga, M. *see* Peitz, U.  
*sulphide*, 325  
 Sumii, M. *see* Ito, M.  
 Sung, J.J.Y. *see* Cheng, A.S.L.  
 Sung, J.J.Y. *see* Leong, R.W.L.  
 Sung, J.J.Y. *see* Leung, W.K.  
 Sung, J.J.Y. *see* Wu, J.C.Y.  
*surgery*, 27  
 Suyenobu, B. *see* Mayer, E.A.  
 Suzuki, H. *see* Suzuki, M.  
 Suzuki, K. *see* Suzuki, M.  
 Suzuki, M., Suzuki, H., Kitahora, T., Miyazawa, M., Nagahashi, S., Suzuki, K. & Ishii, H. Treatment with a proton pump inhibitor promotes corpus gastritis in patients with *Helicobacter pylori*-infected antrum-predominant gastritis, 159  
 Svedberg, P., Johansson, S., Wallander, M.-A., Hamelin, B. & Pedersen, N.L. Extra-intestinal manifestations associated with irritable bowel syndrome: a twin study, 975  
 Svensson, H. *see* Hallert, C.  
*Sydney system*, 1923  
*symptoms*, 735  
*systematic review*, 51, 1689  
 Sytgat, G.N.J., Van Nueten, L., Van de Velde, I., Joslyn, A. & Hanauer, S.B. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicenter randomized, double-blind studies, 87  
 Szeto, M.L. *see* Hung, W.K.  
 Szeto, M.L. *see* Yee, Y.K.  
 Szilagyi, A. Review article: lactose — a potential prebiotic, 1591  
 Takashima, M. *see* Furuta, T.  
 Talbot, I.C. *see* Mimura, T.  
 Talbot, I.C. *see* Van Den Bogaerde, J.  
 Talley, N.J. *see* Eslick, G.D.  
 Talley, N.J. *see* Holtmann, G.  
 Tami, J. *see* Yacyszyn, B.R.  
 Tanaka, S. *see* Ito, M.  
 Tang, V.S.Y. *see* Wong, W.M.  
 Tang, V.S.Y. *see* Xia, H.H.-X.  
 Tankova, L., Yoncheva, K., Muhtarov, M., Kadyan, H. & Draganov, V. Topical mononitrate treatment in patients with anal fissure, 101  
 Tatsuguchi, A. *see* Futagami, S.  
 Taupo, T. *see* Verghese, V.J.  
 Tchienbou, J. *see* Gournay, J.  
*tegaserod*, 1701, 1877  
 Tejura, B. *see* Warrington, S.  
 Tendler, D.A. *see* Spechler, S.J.  
 Tessieri, L. *see* Bilardi, C.  
 Tessieri, L. *see* Zentilin, P.  
 Testa, E. *see* Giannini, E.  
 Testa, E. *see* Zentilin, P.  
 Testa, R. *see* Giannini, E.  
*tetracycline*, 569, 1457  
 Thabut, D. *see* Goulenok, C.  
*thalidomide*, 1117, 2115  
*therapeutic use*, 27  
 The Axys Ulcerative Colitis Study Group. *see* Tremaine, W.J.  
 The Clafoam Study Group. *see* Malchow, H.  
 The European *Helicobacter Pylori* Study Group (EHPGS), *see* Mallertheiner, P.  
 The Group for Eradication Studies from Catalonia, Aragón (GRESCA), *see* Calvet, X.  
 The Group d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID), *see* Abitbol, V.  
 The Italian Gastric Lymphoma Study Group. *see* Caletti, G.  
 The Pantoprazole US GERD Study Group B. *see* Kovacs, T.O.G.

- the rHIL-11 Crohn's Study Group. *see* Sands, B.E.
- Therapondos, G. *see* Tripathi, D.
- therapy, 1, 527
- thiopurine methyltransferase activity, 389
- thiopurine methyltransferase, 79, 1743
- thiopurines, 1831
- Thomas, C. *see* Massironi, S.
- Thomas, G.A.O. *see* Hawkes, N.D.
- Thomforde, G. *see* Kuo, B.
- Thompson Coon, J. & Ernst, E. Systematic review: herbal medicinal products for non-ulcer dyspepsia, 1689
- Thompson, B.F., Arguedas, M.R. & Wilcox, C.M. Antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in patients with obstructive jaundice: is it worth the cost?, 727
- Thompson, W.G. *see* Camilleri, M.
- Thompson, W.G. Review article: the treatment of irritable bowel syndrome, 1395
- Thomson, A.B.R. *see* Huang, J.-Q.
- thoracic and lumbar spine, 1519
- Thornton, P.C. *see* Green, J.R.B.
- Thornton, P.C. *see* Mansfield, J.C.
- three-day rule, 1011
- thromboxane, 1683
- tinidazole, 145
- Tinto, A., Lloyd, D.A.J., Kang, J.-Y., Majeed, A., Ellis, C., Williamson, R.C.N. & Maxwell, J.D. Acute and chronic pancreatitis—diseases on the rise: a study of hospital admissions in England 1989/90–1999/2000, 2097
- Tinto, A. *see* Kang, J.-Y.
- Tito, L. *see* Calvet, X.
- TLOS, 1655
- T-lymphocytes, 1021
- To, K.F. *see* Cheng, A.S.L.
- Togliani, T. *see* Caletti, G.
- Tolley, K. *see* Klok, R.M.
- Tondu, F. *see* Marteau, P.
- Tong, T.S.M. *see* Hung, W.K.
- Torrente, F. *see* Barabino, A.
- Tositti, G. *see* Fabris, P.
- Tougas, G., Snape Jr, W.J., Otten, M.H., Earnest, D.L., Langaker, K.-E., Pruitt, R.E., Pecher, E., Nault, B. & Rojavin, M.A. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome, 1701
- toxicity, 1743
- toxicity prognosis, 707
- TPMT, 1743
- transient lower oesophageal sphincter relaxation, 17, 743
- transit, 603
- Travis, S. *see* Fraser, A.G.
- treatment, 683, 1047, 1125, 1157, 1407
- treatment-response, 1641
- Treem, W.R. *see* Orenstein, S.R.
- Tremaine, W. *see* Kane, S.V.
- Tremaine, W.J., Brzezinski, A., Katz, J.A., Wolf, D.C., Fleming, T.J., Mordenti, J., Strenkoski-Nix, L.C., Kurth, M.C. & the Axy's Ulcerative Colitis Study Group. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study, 407
- Triadafilopoulos, G. *see* Passaro, D.J.
- Triantafyllou, K. *see* Georgopoulos, S.D.
- triglycerides, 577
- Trimpath, J.D. & Giardiello, F.M. Review article: genetic testing and counselling for hereditary colorectal cancer, 1843
- Tripathi, D., Therapondos, G., Lui, H.F., Stanley, A.J. & Hayes, P.C. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating  $\beta$ -blocker, in patients with cirrhosis and portal hypertension, 373
- triple eradication therapy, 1933
- triple therapy, 137, 145, 153, 1149, 1261, 1669, 2107
- Trotter, J.F. *see* Hayashi, P.H.
- tryptase inhibitor, 407
- Tsiaooussis, J. *see* Athanasakis, E.
- Tsukui, T. *see* Futagami, S.
- Tu, T.-C. *see* Liao, C.-C.
- Tuleu, C., Basit, A.W., Waddington, W.A., Ell, P.J. & Newton, J.M. Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules, 1771
- tumour necrosis factor  $\alpha$ , 2115
- Tura, S. *see* Caletti, G.
- Tutuian, R., Katz, P.O., Ahmed, F., Korn, S. & Castell, D.O. Over-the-counter  $H_2$ -receptor antagonists do not compromise intragastric pH control with proton pump inhibitors, 473
- Tutuian, R., Katz, P.O., Bochenek, W. & Castell, D.O. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers, 829
- twins, 975
- Tytgat, G. *see* Malfertheiner, P.
- Tytgat, G.N.J. *see* Hirsch, D.P.
- Tytgat, G.N.J. *see* Kuiken, S.D.
- ulceration, 1917
- ulcerative colitis, 27, 61, 69, 87, 197, 207, 325, 407, 693, 699, 919, 1109, 1125, 1225, 1233, 1743, 1751, 1889, 1895, 2061
- Ullrich, H., Avenhaus, W., Poremba, C., Domschke, W. & Menzel, J. High-dose interferon  $\alpha$ -2a with ribavirin and amantadine in naïve chronic hepatitis C patients — results of a randomized, prospective, pilot study, 2107
- ultrasonography, 129
- upper gastrointestinal bleeding, 497
- upper gastrointestinal endoscopy, 105, 111
- upper gastrointestinal malignancies, 1011
- urea breath test, 137, 1443, 1733
- Usadel, K.-H. *see* Braden, B.
- Vaira, D. *see* Palli, D.
- Vaira, D. *see* Voland, P.
- Vaizey, C.J. *see* Van Den Bogaerde, J.

- Vakil, N., Rydén-Bergsten, T. & Bergenheim, K. Systematic review: patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease, 1469
- Valdimarsson, T. *see* Hallert, C.
- Valero, C. *see* Calvet, X.
- Vallve, M., Vergara, M., Gisbert, J.P. & Calvet, X. Single vs. double dose of a proton pump inhibitor in triple therapy for *Helicobacter pylori* eradication: a meta-analysis, 1149
- Valpiani, D. *see* Rizzello, F.
- Van Acker, K.L. *see* De Block, C.E.M.
- van Balkom, B.P.J., Schoon, E.J., Stockbrügger, R.W., Wolters, F.L., van Hogezaand, R.A., van Deventer, S.J.H., Oldenburg, B., van Dullemen, H.M. & Russel, M.G.V.M. Effects of anti-tumour necrosis factor- $\alpha$  therapy on the quality of life in Crohn's disease, 1101
- Van Berge Henegouwen, G.P. *see* Clemens, C.H.M.
- Van De Casteele, M., Zaman, Z., Zeegers, M., Servaes, R., Fevery, J. & Nevens, F. Blood antioxidant levels in patients with alcoholic liver disease correlate with the degree of liver impairment and are not specific to alcoholic liver injury itself, 985
- Van de Velde, I. *see* Sytgal, G.N.J.
- van den Berg, P.B. *see* Klok, R.M.
- Van Den Bogaerde, J., Cahill, J., Emmanuel, A.V., Vaizey, C.J., Talbot, I.C., Knight, S.C. & Kamm, M.A. Gut mucosal response to food antigens in Crohn's disease, 1903
- van Deventer, S.J.H. *see* van Balkom, B.P.J.
- van Dullemen, H.M. *see* van Balkom, B.P.J.
- Van Gaal, L.F. *see* De Block, C.E.M.
- Van Haarst, A.D. *see* Kamerling, I.M.C.
- Van Hecken, A., Juliano, M.L., Depré, M., De Lepeleire, I., Arnout, J., Dynder, A., Wildonger, L., Petty, K.J., Gottesdiener, K. & De Hoon, J.N. Effects of enteric-coated, low-dose aspirin on parameters of platelet function, 1683
- Van Herwaarden, M.A., Samsom, M., Rydholm, H. & Smout, A.J.P.M. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease, 1655
- van Hogezaand, R.A. *see* van Balkom, B.P.J.
- Van Hoof, V. *see* De Block, C.E.M.
- Van Marck, E.A.E. *see* De Block, C.E.M.
- Van Nueten, L. *see* Sytgal, G.N.J.
- Van Oene, J.C. *see* Sloots, C.E.J.
- Van Rossum, L.G.M. *see* Laheij, R.J.F.
- Van Vlierberghe, H., Verdiev, H., Colle, L., Delanghe, J., Praet, M., Bernard, D., Leroux-Roels, G. & De Vos, M. Non-transferrin-bound iron in untreated and ribavirin-treated chronic hepatitis C patients, 1555
- Vanasia, M. *see* Distrutti, E.
- Vanheuverzwyn, R. *see* Dewit, O.
- Varga, L. *see* Netzer, P.
- Varoli, G. *see* Rizzello, F.
- Veitch, A. *see* Zulu, I.
- Veldhuyzen van Zanten, S.J.O. *see* Malfertheiner, P.
- Ventura, A. *see* Barabino, A.
- Verdiev, H. *see* Van Vlierberghe, H.
- Vergara, M. *see* Vallve, M.
- Verghese, V.J., Ayub, K., Qureshi, W., Taupo, T. & Graham, D.Y. Low-salt bowel cleansing preparation (LoSo Prep) as preparation for colonoscopy: a pilot study, 1327
- Verlinden, M.H. *see* Chen, C.L.
- Verspaget, H.W. *see* Kruidenier, L.
- Vigneri, S. *see* Bilardi, C.
- Vigneri, S. *see* Zentilin, P.
- Vilei, M.T. *see* Pazzi, P.
- Villarejo, J. *see* Sabate, J.M.
- Viramontes, B. *see* Kuo, B.
- visceral pain, 1357
- Viscido, A. *see* Caprilli, R.
- vitamin D, 919, 1895
- vitamin intake, 1333
- Vogt, B. *see* Mayer, E.A.
- Voland, P., Weeks, D.L., Vaira, D., Prinz, C. & Sachs, G. Specific identification of three low molecular weight membrane-associated antigens of *Helicobacter pylori*, 533
- Von Arnim, U. *see* Peitz, U.
- Wada, K. *see* Futagami, S.
- Waddington, W.A. *see* Tuleu, C.
- Wai, C.T. *see* Lim, L.L.
- Wakfield, A.J., Puleston, J.M., Montgomery, S.M., Anthony, A., O'Leary, J.J. & Murch, S.H. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands, 663
- Wallander, M.-A. *see* Svedberg, P.
- Wang, W.-C. *see* Poon, S.K.
- Wang, W.H. *see* Wong, W.M.
- Wang, Y.-L. *see* Sheu, B.-S.
- Ward, E.M. & Wolfsen, H.C. Review article: the non-inherited gastrointestinal polyposis syndromes, 333
- Warrington, S., Baisley, K., Boyce, M., Tejura, B., Morocutti, A. & Miller, N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects, 1301
- Watanabe, H. *see* Rugge, M.
- Watts, D. *see* Arnott, I.D.R.
- Weeks, D.L. *see* Voland, P.
- Weir, D.G. *see* Mahmud, N.
- Whitman, R. *see* Pehlivanov, N.
- Whittington, C.A. & Kowdley, K.V. Review article: haemochromatosis 1963
- Wicks, A.C. *see* Khan, Z.
- Wicks, A.C.B. *see* Massironi, S.
- Wienbeck, M. *see* Hallerbäck, B.
- Wilcox, C.M. *see* Kovacs, T.O.G.
- Wilcox, C.M. *see* Thompson, B.F.
- Wildi, S. *see* Netzer, P.
- Wildonger, L. *see* Van Hecken, A.
- Wilkins, R. *see* Sands, B.E.
- Williamson, R.C.N. *see* Tinto, A.
- Winston, B.D. *see* Sands, B.E.
- Wolf, D.C. *see* Tremaine, W.J.
- Wolfsen, H.C. *see* Ward, E.M.
- Wolle, K. *see* Peitz, U.

- Wolters, F.L. *see* van Balkom, B.P.J.
- Wong, B.C.Y. *see* Hu, W.H.C.
- Wong, B.C.Y. *see* Hung, W.K.
- Wong, B.C.Y. *see* Ng, F.H.
- Wong, B.C.Y. *see* Wong, W.-M.
- Wong, B.C.Y. *see* Wong, W.M.
- Wong, B.C.Y. *see* Xia, H.H.-X.
- Wong, G.S.W. *see* Hung, W.K.
- Wong, S.K.H. *see* Wu, J.C.Y.
- Wong, S.W. *see* Yee, Y.K.
- Wong, S.Y. *see* Ng, F.H.
- Wong, T. *see* Lamb, E.J.
- Wong, W.-M., Lai, K.C., Lau, C.P., Hu, W.H.C., Chen, W.H., Wong, B.C.Y., Hui, W.M., Wong, Y.H., Xia, H.H.X. & Lam, S.K. Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain. 465
- Wong, W.-M., Lam, S.K., Hui, W.M., Lai, K.C., Chan, C.K., Hu, W.H.C., Xia, H.H.X., Hui, C.K., Yuen, M.F., Chan, A.O.O. & Wong, B.C.Y. Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese — prevalence and spectrum of the disease. 2037
- Wong, W.M., Wong, B.C.Y., Lu, H., Gu, Q., Yin, Y., Wang, W.H., Fung, F.M.Y., Lai, K.C., Xia, H.H.X., Xiao, S.D. & Lam, S.K. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of *Helicobacter pylori* eradication with standard triple therapies. 793
- Wong, W.M., Wong, B.C.Y., Xia, H.H.X., Tang, V.S.Y., Lai, K.C., Hu, W.H.C., Yuen, M.F., Chan, C.K. & Lam, S.K. An evaluation of a rapid urine test for the diagnosis of *Helicobacter pylori* infection in the Chinese population. 813
- Wong, W.-M. *see* Hu, W.H.C.
- Wong, W.-M. *see* Hui, C.-K.
- Wong, W.M. *see* Hung, W.K.
- Wong, W.M. *see* Ng, F.H.
- Wong, W.M. *see* Xia, H.H.-X.
- Wong, Y.H. *see* Wong, W.-M.
- Wood, M. *see* Malik, A.H.
- Woolner, J. *see* Middleton, S.J.
- Wrangstadh, M. *see* Malfertheiner, P.
- Wright, N.A. *see* Khan, Z.
- Wright, N.A. *see* Sasaki, M.
- Wruble, L. *see* Sands, B.E.
- Wu, C.-H. *see* Liao, C.-C.
- Wu, H.-W. *see* Sheu, B.-S.
- Wu, J.C.Y., Chan, F.K.L., Wong, S.K.H., Lee, Y.T., Leung, W.K. & Sung, J.J.Y. Effect of *Helicobacter pylori* eradication on oesophageal acid exposure in patients with reflux oesophagitis. 545
- Wu, J.-J. *see* Sheu, B.-S.
- Xia, H.H.-X., Wong, B.C.Y., Wong, W.M., Tang, V.S.Y., Cheung, H.K.L., Sham, F.N.F., Fung, F.M.Y., Lai, K.C., Hu, W.H.C., Chan, C.K. & Lam, S.K. Optimal serological tests for the detection of *Helicobacter pylori* infection in the Chinese population. 521
- Xia, H.H.-X. *see* Eslick, G.D.
- Xia, H.H.X. *see* Hung, W.K.
- Xia, H.H.X. *see* Wong, W.-M.
- Xia, H.H.X. *see* Wong, W.M.
- Xia, H.X.H. *see* Hu, W.H.C.
- Xiao, F. *see* Furuta, T.
- Xiao, F. *see* Shirai, N.
- Xiao, S.D. *see* Wong, W.M.
- Xynos, E. *see* Athanasakis, E.
- Yacyshyn, B.R., Barish, C., Goff, J., Dalke, D., Gaspari, M., Yu, R., Tami, J., Dorr, F.A. & Sewell, K.L. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. 1761
- Yan, P. *see* Eslick, G.D.
- Yang, C.C. *see* Poon, S.K.
- Yang, H.-B. *see* Sheu, B.-S.
- Yang, U.S. *see* Choi, I.J.
- Yarbrough, K. *see* Malik, A.H.
- Yee, Y.K., Yip, K.T., Que, T.L., Chang, K.K., Li, K.F., Lee, C.K., Wong, S.W., Lau, S.F. & Szeto, M.L. Efficacy of enzyme immunoassay for the detection of *Helicobacter pylori* antigens in frozen stool specimens: local validation. 1739
- Yim, A. *see* Ansari, A.
- Yin, Y. *see* Wong, W.M.
- Yip, A.W.C. *see* Hung, W.K.
- Yip, K.T. *see* Yee, Y.K.
- yogurt. 1669
- Yoncheva, K. *see* Tankova, L.
- Yoshihara, M. *see* Ito, M.
- Yoshikawa, I., Murata, I., Kume, K., Kanagawa, K., Hirohata, Y., Nakamura, H. & Otsuki, M. Serum pepsinogen can predict response to H<sub>2</sub>-receptor antagonist in patients with functional dyspepsia. 1805
- You, J.H.S., Lee, K.K.C., Chan, T.Y.K., Lau, W.H. & Chan, F.K.L. Arthritis treatment in Hong Kong — cost analysis of celecoxib versus conventional NSAIDs, with or without gastroprotective agents. 2089
- Yu, R. *see* Yacyshyn, B.R.
- Yuen, M.-F. *see* Hui, C.-K.
- Yuen, M.F. *see* Hung, W.K.
- Yuen, M.F. *see* Wong, W.-M.
- Yuen, M.F. *see* Wong, W.M.
- Yuen, W.C. *see* Ng, F.H.
- Yuki, M. *see* Adachi, K.
- Zagari, R.M. *see* Bazzoli, F.
- Zaman, Z. *see* Van De Casteele, M.
- Zambia. 595
- Zar, S., Benson, M.J. & Kumar, D. Review article: bloating in functional bowel disorders. 1867
- Zeegers, M. *see* Van De Casteele, M.
- Zeijlon, L. *see* Malfertheiner, P.
- Zentilin, P., Conio, M., Mele, M.R., Mansi, C., Pandolfo, N., Dulbecco, P., Gambaro, C., Tessieri, L., Iiritano, E., Bilardi, C., Biagini, R., Vigneri, S. & Savarino, V. Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. 893

- Zentilin, P., Serio, B., Dulbecco, P., Caratto, E., Iiritano, E.,  
Fasciolo, D., Bilardi, C., Mansi, C., Testa, E. & Savarino, V.  
Eradication of *Helicobacter pylori* may reduce disease severity in  
rheumatoid arthritis. 1291
- Zentilin, P. *see* Bilardi, C.
- Zinicola, R. *see* Falasco, G.
- Zinzani, P.L. *see* Caletti, G.
- Zocco, M.A. *see* Armuzzi, A.
- Zocco, M.A. *see* Di Caro, S.
- Zollinger–Ellison syndrome. 1367
- Zoras, O.J. *see* Athanasakis, E.
- Zulu, L., Veitch, A., Sianongo, S., McPhail, G., Feakins, R.,  
Farthing, M.J.G. & Kelly, P. Albendazole chemotherapy for  
AIDS-related diarrhoea in Zambia — clinical, parasitological  
and mucosal responses. 595



